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Abstract 
 
TCDD (dioxin) causes immunosuppression via activation of the Aryl hydrocarbon 
receptor (AhR). Dendritic cells (DCs), the professional antigen-presenting cells in 
the immune system, are adversely affected by TCDD. However, limited 
information exists regarding the effects of AhR activation on DCs. We evaluated 
the consequences of AhR activation by TCDD on both steady-state  and 
inflammatory DCs using in vivo and in vitro approaches, respectively.  We 
hypothesized that AhR activation alters DC homeostasis and differentiation 
leading to generation of immunosuppression. C57Bl/6 mice gavaged with an 
immunosuppressive dose of TCDD (15 µg/kg) displayed decreased frequency 
and number of splenic CD11chigh DCs on day 7. Moreover, TCDD induced a 
selective loss of the CD11chighCD8α-33D1+ splenic DCs subset, specialized at 
activating CD4+ T cells, but not the regulatory CD11chighCD8α+DEC205+ splenic 
DCs. Additionally, TCDD increased the expression of CD86 and CD54, while 
decreasing the frequency of CD11a and MHC II on the splenic CD11chigh DCs. 
Although TCDD did not alter the number and frequency of CD11clow splenic DCs, 
it decreased their MHC II and CD11a expression. The loss of CD11chigh DC was 
independent of an apoptotic event but involved a CCR7-mediated migratory 
event. Popliteal and brachial lymph node (PBLNs) CD11c+ cells displayed 
elevated levels of MHC II and CD40, but not DC loss following TCDD exposure. 
To examine the effects of TCDD on inflammatory DCs, BMDCs were generated 
in the presence of GM-CSF and vehicle or TCDD. TCDD decreased CD11c 
expression but increased MHC II, CD86 and CD25 expression on these BMDCs. 
These effects were AhR-dependent but not exclusively DRE-mediated. 
Additionally, TCDD modulated antigen uptake and increased LPS- and CpG-
induced IL-6 and TNF-α levels but decreased nitric oxide production by the 
BMDCs. TCDD downregulated LPS- and CpG-induced p65 levels and induced a 
trend towards upregulation of RelB levels in BMDCs. Despite the induction of 
suppressive mediators IDO1, IDO2 and TGFβ3, TCDD-BMDCs failed to 
suppress T cell activation in vivo or induce the generation of adaptive T-regs in 
vitro. Collectively, our data suggest that AhR activation disrupts DC homeostasis, 
modulates DC differentiation, TLR responsiveness and induces a regulatory 
phenotype, effects that may underlie TCDD-induced immunosuppression. 
 
 
 
 
 iii 
 
 
ACKNOWLEDGEMENT 
 
 
Foremost, I owe my deepest gratitude to my mentor Dr. David Shepherd for his 
continuous support, motivation and patience. I thank him for devoting his time 
and attention to my scientific development. I am also thankful to all committee 
members for all their help and guidance during my doctoral study.  
 
My lab mates in the Shepherd lab always added a component of humor and fun 
to lab work. Specially, I would like to thank Andrea and Tom for their relentless 
help, teamwork and friendship. I enjoyed every bit of working with them.  Andrea, 
Tom, Maria, Alison and Teri thanks for all the support, entertaintment and care. 
Thank you all for creating a supportive and fun environment. A very special 
thanks to my friends Miranda, Shikha and Trideep for their support and 
encouragement at all times. Pam, thanks for all your moral support and selfless 
help. I am also very grateful to Dr. Celine Beamer for her immense help, insight 
and guidance at multiple occasions and numerous ways during my doctoral 
study.  
 
Lastly, and most importantly, I would like to thank my family. This work would not 
have been possible without their support. Ma and Pa thanks for your 
unconditional support and care. To my siblings, Brijesh bhai and Rashmi, 
hopefully you take me seriously now!  
 
 
 
 
 
 
 
 iv 
 
TABLE OF CONTENTS 
 
CHAPTER 1: Introduction…..…………...………………….………………………..1 
The Immune system…………………………………………………………….1 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).……...………………………..14  
Aryl hydrocarbon receptor…………………………………..………………..16 
TCDD-induced toxicity in animals……………………………………….…...21 
AhR knockout, mutant and transgenic mice………………..………...….…23 
TCDD toxicity in humans………………………………….………….……….25 
TCDD Immunotoxicity………………………………………………………....30 
AhR activation by ligands other than TCDD…………………..…..………..36 
Hypothesis……………………………………………………………………...39 
References………………………………………………………………..……44 
 
CHAPTER 2: Effects of TCDD on the fate of naïve dendritic cells…………..58 
Abstract………………………………...………………………………….……59 
Introduction……………………………………………………………………..61 
Materials and Methods……………………………………………......………64 
Results………………………………………………………………………….68 
Discussion ………………..……………………………………………………83 
References…………………………………………………..…………………92 
 
CHAPTER 3: Functional and phenotypic effects of AhR activation in 
murine, bone marrow-derived dendritic cells……………………….……….…96 
Abstract……………………………………………………………….…….…..97 
Introduction………………………………………………………………..……99 
Materials and Methods…………………………………………………..…..102 
Results………………………………………………………….……………..106 
Discussion…………………………………………………………………….122 
References…………………………..………………………………………..131 
 v 
 
CHAPTER 4: AhR-activation in dendritic cells and the generation of 
regulatory T cells…………………………………………………………...………135 
Abstract………………………………………………………………………..136 
Introduction……………………………………………………………………138 
Materials and Methods………………………………………………………140 
Results……………………………………………………………...…………144 
Discussion………………………………………………………….…………153 
References……………………………………………………………………158 
 
CHAPTER 5: Conclusions….…………………………………….……………….161 
 References…………………………………………………….…..………….167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
 
LIST OF FIGURES 
 
1-1 The three signal hypothesis…………………………………………………….…3 
1-2 The distribution of TLRs……………………………………………………………6 
1-3 Overview of canonical and non-canonical NF-kB signaling pathway…….….11 
1-4 Chemical structures of various halogenated hydrocarbons…………………..15 
1-5 The classical AhR signaling pathway…………………………………………...18 
 
2-1 (A) CD11c expression on DCs from peripheral immune tissues. (B) AhR 
protein levels in splenic CD11chigh and CD11clow DCs…………………………….69  
2-2 TCDD induces a loss of splenic CD11chigh but not CD11clow DCs………..….70 
2-3 The number and percentage of splenic CD11chigh DCs in lpr and gld animals 
are decreased following TCDD exposure……………………………………….…..75 
2-4 TCDD increases CCR7 expression on splenic CD11chigh DCs……………...78 
2-5 Effects of TCDD on DCs in the peripheral lymph nodes……………………...80 
2-6 Expression of CCR7 is increased on DCs from lymph nodes following TCDD 
exposure………………………………………………………………………………..82 
2-7 Schematic diagram of the effects of TCDD on splenic CD11chighDCs...........90 
 
3-1 TCDD alters the expression of differentiation markers on BMDCs.………..108 
3-2 Low concentrations of TCDD alter BMDC differentiation…………...……....109 
3-3 Natural AhR agonists alter BMDC differentiation…………………………….110 
3-4Effects of TCDD on BMDCs are AhR-dependent and partially DRE-
dependent……………………………………………………………………………..112 
3-5 Effects of TCDD on LPS-and CpG–induced MHC Class IIhigh expression...113 
3-6 LPS-and CpG-induced p65 but not Rel B activity is reduced by TCDD…...115 
3-7 TCDD alters antigen uptake by BMDCs……………………………………....118 
3-8 Ability of TCDD-treated BMDCs to activate antigen-specific T cells….…...120 
 
 
 vii 
4-1 Effects of TCDD-treated BMDCs on the generation of Foxp3+ Tregs from 
conventional CD4+ T cells…………………………………………………………...151 
4-2 Effects of LPS-matured, TCDD-treated ova-peptide loaded BMDCs on 
antigen-specific T cell proliferation in vivo…………………………………………152 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
 
LIST OF TABLES 
 
1-1 Different types of dendritic cells…………………………………………………..9 
1-2 The diverse range of natural and non-TCDD AhR ligands…………………...38 
2-1 Effects of TCDD on the expression of key accessory molecules on splenic 
DCs………….…………………………………………………………………………..72 
2-2 Effects of TCDD on splenic DC subsets………………………………………..73 
2-3 Exposure to TCDD does not induce apoptosis…………………………...…...77 
2-4 Effects of TCDD on the expression of accessory molecules on DCs from 
peripheral lymph nodes……………………………………………………………….81 
3-1 Effects of TCDD on the number of murine bone marrow dendritic cells…..107 
3-2 Effects of AhR activation on cytokine production by BMDCs…………..…..116 
3-3 AhR activation alters gene expression………………………………………..119 
4-1 The AhR is required for TCDD-induced changes in the expression of 
regulatory mediators………………………………………………………………....145 
4-2 Role of DREs-mediated events in the TCDD-induced gene expression of 
regulatory mediators in BMDCs………………………………………………….…146 
4-3 AhR activation by natural ligand FICZ alters gene expression…………..…148 
4-4 Effects of 8 hours LPS stimulation on TCDD-induced regulatory gene 
expression in BMDCs…………….....……………………………………………....150
 
 
  
 
 
 
 
 
 1 
 
CHAPTER 1 
INTRODUCTION 
This study describes the effect of Aryl hydrocarbon receptor (AhR) 
activation on the fate and function of dendritic cells (DCs). The introductory 
chapter will: 1) broadly describe the immune system with a central focus on DCs 
and T cells 2) provide detailed information on 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD) and the AhR, and lastly 3) describe TCDD immunotoxicity. 
The Immune system 
 Following entry of a pathogenic organism in our body, the immune system 
is activated to limit the pathogenic insult to the host. The immune system 
achieves this function in a series of coordinated steps carried out by two 
specialized branches referred to as the innate and the adaptive immune system. 
Although the central purpose of both is to protect the host, the innate and the 
adaptive immune system differ in their mode of action as described below.  
Innate Immune System: The innate immune system constitutes the first line of 
defense against pathogenic insult and encompasses anatomical, physiological, 
phagocytic, and inflammatory barriers. The anatomical barrier consists of skin, 
epithelial layers and mucous membranes, which form an immediate physical 
barrier to most infectious agents preventing their direct entry into the body. The 
physiological barrier includes fatty acids, enzymes such as lysozyme, and 
antibacterial peptides that further prevent pathogen establishment. Additionally, 
the normal flora of the body secretes factors that are detrimental to pathogens 
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and prevent colonization. Pathogens that escape these initial barriers, encounter 
specialized cells of the innate immune system, which consists of neutrophils, 
macrophages, natural killer cells, eosinophils and dendritic cells (DCs). These 
may phagocytose the pathogen thereby killing it intracellularly. Alternately, 
certain innate immune cells may also process and present portions of the 
pathogen to adaptive immune cells such as T cells and B cells. In this capacity, 
macrophages and DCs are referred as antigen presenting cells (APCs). These 
cells express cell surface proteins as well as secrete soluble inflammatory 
mediators that serve to attract and stimulate the adaptive immune cells at the site 
of injury as well as the draining lymph nodes. 
Antigen presenting cells: Antigen presenting cells function to detect pathogen 
in the periphery, process and present it to the lymphocytes in the draining lymph 
nodes and subsequently activate the adaptive immune system.  In addition to the 
ubiquitously expressed major histocompatibiliy antigen I (MHC I), APCs express 
MHC II and B7 molecules also known as CD80 (B7-1) and CD86 (B7-2) (Bryant 
and Ploegh, 2004). Effective activation of T cell by an APC is described using the 
three-signal hypothesis. As shown in Figure 1-1, three signals are necessary for 
complete activation of T cell by APCs. Signal one comprises delivery of the MHC 
bound antigen to the T cell receptor (TCR). Signal two constitutes the binding of 
B7 co-stimulatory signals to cognate CD28 receptors on T cells. Secretion of 
soluble mediators, such as cytokines from activated APCs constitutes signal 
three. The nature of the secreted cytokine in turn governs T cell polarization as 
discussed later in this chapter (Goldsby, 2003).  Appropriate and timely delivery  
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Figure 1-1 
 
 
 
 
 
Figure 1-1. Effective activation of a T cell by an APC is dependent on three 
signals. Signal 1 is the interaction of MHC bound Ag with the T cell receptor. 
Binding of costimulatory molecules expressed on DC with cognate molecules on 
the T cells generates signal 2.  APCs also secrete cytokines that contribute to T 
cell polarization, and this interaction constitutes signal 3.The lack of these signals 
leads to T cell anergy, depletion or tolerance. Adapted from Cools et al., 2007. 
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of the three signals is required for a sucessful T cell response. A lack of these 
signals can lead to anergy, deletion or tolerance. Anergy refers to a state in 
which a T cell is inactivated and hyporesponsive. For instance, delivery of signal 
1 in the absence of costimulation can lead to T cell anergy. Additionally, 
maturational state of an APC also influences the development of a T cell 
response as discussed in the following section.  
Dendritic cells: Amongst the existing varieties of APCs, DCs are considered the 
most potent APCs that execute both innate and adaptive functions.  DCs 
constitute part of the first line of defense against invading pathogens and play a 
critical role in the generation of effective innate immunity to pathogenic 
challenge. Crucial functions of DCs include their ability to take up antigens, 
secrete cytokines, and recognize unique pathogen associated molecular patterns 
(PAMPs) via pattern recognition receptors (PRRs). The PRRs such as the toll 
like receptors (TLRs) encompasses membrane-bound receptors such as TLR4, 
and intracellular receptors such as TLR9.  As shown in Figure 1-2, TLR4 
recognizes lipopolysaacharide (LPS), whereas TLR9 specifically recognizes 
cytosine phosphate guanine (CpG) motif. TLR stimulation activates DCs leading 
to the secretion of proinflammatory cytokines such as TNF-α and IL-6, which 
further modulate the developing immune response by orchestrating T cell 
polarization. 
 In addition, DCs also regulate adaptive immunity and are considered to be 
the most potent for initiating activation of naïve T cells. Concomitant with the 
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constitutively high expression of MHC II, DCs also express T cell costimulatory 
molecules such as CD80 and CD86 (Greenwald et al., 2005). Following 
encounter with pathogen or host-derived inflammatory products such as 
cytokines, immature DCs are induced to mature. This maturation is associated 
with upregulation of chemokine receptors such as CCR7 resulting in migration to 
the lymph nodes, where subsequent interactions with T cells lead to generation 
of adaptive immunity (Sanchez-Sanchez et al., 2006). As shown in Figure 1-1, 
activation of a T cell by a DC requires three signals. In the most traditional form 
of antigen (Ag) presentation, DCs uptake antigen and present short, Ag-derived 
peptides, bound to MHC to the T cell. Intracellulary-derived Ag such as viral 
products are usually presented via MHC I molecules to the TCR of CD8+ T cells, 
and exogenously-derived antigen such as bacterial products are presented via 
MHC II to the TCR of CD4+ T cells (Cresswell, 2005). Following receptor 
engagement, costimulatory molecules on DCs such as CD80 and CD86 bind and 
activate surface receptors expressed on T cells such as CD28 (Lenschow et al., 
1996). Other accessory molecules such as CD54:CD11a  and CD40:CD154 also 
play important roles in T cell activation  (Croft and Dubey, 1997).  Final 
differentiation of a T cell into an effector cell is mediated by cytokines secreted by 
the DCs and other immune and non-immune cells. Therefore, full T cell activation 
and generation of an immunogenic response is dependent on appropriate and 
timely presentation of three distinct signals. 
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Figure 1-2 
 
 
   
Figure 1-2. TLRs and their ligands: Dendritic cells express both surface bound 
and intracellular TLRs. Binding of ligands to their respective TLR activates a 
signaling cascade leading to induction of downstream transcription factors and 
drives the activation and maturation of DCs.  
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  An accumulating body of evidence suggests that DCs also function to 
generate and maintain Ag-specific unresponsiveness in central and peripheral 
immune tissues (Steinman et al., 2003). Such DCs are referred to as tolerogenic 
or regulatory DCs (DCregs). There are multiple ways in which DCs can induce T 
cell tolerance. For instance, T cells are tolerized when their TCR engages 
peptide-MHC complexes on an immature DC (Forster and Lieberam, 1996; Kurts 
et al., 1996). Alternately, numerous studies have shown that Ag presentation in 
the absence of co-stimulation leads to T cell anergy (Adler et al., 1998; Schwartz, 
2003; Cools et al., 2007). Similarly, DCs expressing low levels of MHC Class II 
and costimulatory molecules are also inefficient at inducing T cell activation (Lutz 
et al., 2000). Recently, DCregs have been characterized by the expression of 
maturation markers and the immune-inhibitory enzyme indoleamine 2,3 
dioxygenase (IDO) (Mellor and Munn, 2004; Popov and Schultze, 2008). IDO 
enzymatically degrades the essential amino acid tryptophan generating 
metabolites known as kynurenines which block T-cell proliferation resulting in T 
cell apoptosis (Grohmann et al., 2003). In addtion to expression of IDO,  
interaction of CD86 on a DC with CTLA4 expressed on T cell is also shown 
suppress  T cell responses. 
 DCs are a heterogeneous immune cell population (Vremec et al., 2000; 
Shortman and Liu, 2002). Initial attempts to classify DCs focused on the idea that 
there were two distinct DC lineages: myeloid DCs and lymphoid DCs. It has 
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become increasingly evident, however, that multiple DCs subsets exist beyond 
this. Currently, DCs are classified into three distinct cell types: pre DCs, 
conventional DCs and inflammatory DCs (Table 1-1) (Shortman and Naik, 2007). 
Pre DCs such as plasmacytoid DCs (pDCs) and monocytes develop into DCs 
following an inflammatory or microbial stimulus (Shortman and Naik, 2007). 
Conventional DCs can be further categorized into migratory DCs and lymphoid-
tissue-resident DCs. Lymphoid-resident DCs as the name suggests, reside in the 
lymphoid tissue and exhibit no migratory capacity. In the spleen, these DCs are 
further classified into 2 subtypes based on the presence of the marker CD8α, 
and are referred to as CD8α+DEC205-and CD8α-33D1+. The aforementioned 
splenic DC subsets differ in their anatomic location and functional properties.  
CD8α+DEC205+ DCs reside in the T cell zone and specialize in the uptake of 
dying cells (Dudziak et al., 2007). More recently, a Treg-inducing function has 
been ascribed to these DCs (Yamazaki et al., 2008). In contrast, CD8α-33D1+ 
DCs found in the marginal zone specialize in CD4+ T cell activation (Dudziak et 
al., 2007). In addition, inflammatory DCs constitute a novel DC population that 
are absent in the steady-state and only appear following an inflammatory insult. 
These DCs, characterized by copious production of TNF-α and inducible NO 
synthase (iNOS), are derived in vitro using GM-CSF/IL4 (Xu et al., 2007). 
 Even with such heterogeneity, DCs constitute a very limited pool of the total 
immune cell population and the number of DCs obtainable from an animal is 
extremely limited. Thus, various strategies using bone marrow precursors have 
emerged to generate large number of DCs in culture. DC populations may be 
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Table 1-1: Different types of dendritic cells. Adapted from (Shortman and Naik, 
2007) 
 
 
 
Types of dendritic cells 
 
Pre-dendritic cells 
Exhibit capacity to develop into DCs 
Examples: pDCs, monocytes 
 
 
Conventional dendritic cells 
 
Migratory dendritic cells 
Migrate to the lymphoid areas following Ag capture from the periphery 
Examples: Langerhan cells, dermal DCs 
 
Lymphoid-tissue resident dendritic cells 
Do not migrate to the lymphoid organ 
Spend their life span in one lymphoid organ 
Examples: CD4+CD8-cDCs, CD4-CD8- cDCs and CD4-CD8+ cDCs. 
 
 
Inflammatory dendritic cells 
Absent in the steady-state 
Appear following inflammatory insult 
Examples: Tip DCs 
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generated in vitro using the growth factors Granulocyte Macrophage Colony 
stimulating factor (GM-CSF) and FMS-like tyrosine kinase 3 ligand (Flt3-L). GM-
CSF is widely used for development and expansion of inflammatory DCs in vitro. 
These inflammatory DCs in vitro are characterized by production of TNF-α and 
inducible nitric-oxide-synthase (Tip DCs)(Xu et al., 2007). Flt3-L, on the other 
hand, generates steady-state pDCs and cDCs. Additionally, studies from several 
labs have demonstrated that a single injection of the hematopoietic cytokine, 
Flt3-L enhanced the production of both myeloid and lymphoid DCs that 
encompass both pDCs and cDCs (Maraskovsky et al., 1996; Pulendran et al., 
1999; Brawand et al., 2002; Gilliet et al., 2002). The importance of this cytokine 
in promoting the development of DCs was demonstrated by studies 
demonstrating that Flt3 L KO mice displayed reduced number of pDCs, cDCs 
and NK cells.  
 In addition to the aforementioned growth factors, DC development is 
dependent on the nuclear transcription factor NF-kB, which mediates the 
expression of numerous genes involved in cellular processes such as apoptosis, 
proliferation and inflammation. The mammalian NF-kB transcription family is 
composed of five distinct members: p50, p52, p65 (RelA), c Rel and Relb 
(Moynagh, 2005; Hoffmann et al., 2006). In unstimulated DCs, NF-kB members 
reside in the cytosol in an inactive form via interactions with inhibitory IkB 
proteins. NF-kB signaling ensues in two distinct pathways referred to as the 
canonical signaling pathway and the non-canonical signaling pathway (Figure 1-
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3). The canonical signaling involves activation of the heterodimeric p65-p50  
Figure 1-3         A. 
 
 
 
 
 
 
 
                          B. 
 
 
 
 
 
 
 
Figure 1-3. Overview of canonical and non-canonical NF-kB signaling 
pathways A) The canonical NF-kB signaling pathway involves binding of a 
ligand to a receptor leading to activation of IKK complex. The IKK complex 
degrades IkB leading to translocation of active NF-kB components Rel A and p50 
into the nucleus, where they initiate transcription of genes. B) The non-canonical 
pathway involves binding of a ligand to a receptor, ultimately leading to activation 
of the IKK complex. The IKK complex functions to release the active NF-kB 
components RelB/p52 into the nucleus, where they initiate transcription of genes 
regulated by kB sites. Figure adapted from www.abcam.com. 
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complex and is initiated following binding of a ligand to a cell surface receptor 
such as TLRs.  This leads to recruitment of adaptors such as TRAF to the 
cytoplasmic domain of the receptor followed by recruitment of the IKK complex 
that phosphorylate and degrades the IkB inhibitor, thus releasing the active NF-
kB members (p65-p50). This heterodimeric complex then translocates into the 
nucleus and activates transcription of target genes. The non-canonical signaling 
on the other hand involves activation of p100-RelB complex following 
phosphorylation of p100 through IKK. Although distinct, crosstalk between the 
Canonical and non-canonical NF-kB signaling pathway has been shown to 
regulate inflammatory and developmental signaling (Basak and Hoffmann, 2008). 
Adaptive Immune System: The non-specific nature of the innate immune 
system is often inadequate for the complete clearance of pathogens. In these 
instances, specificity by the immune system is conferred by the adaptive immune 
system as discussed below. The adaptive immune system includes effector cells 
including B and T lymphocytes, which recognize and respond to pathogenic 
insult in an an Ag-specific manner. The Ag-specific nature of the adaptive 
immune system imparts specificity to the immune system and also generates 
immunological memory (Charles A. Janeway, 2005). 
T cells: T cells are hematopoietically-derived cells which originate in the bone 
marrow and reach full maturation in the thymus, where the process of positive 
and negative selection directs their development into two functional types: CD4+ 
and CD8+ T cells. The T cells express the T cell receptor (TCR) that recognises 
and responds to processed antigenic peptides. Full activation of a T cell requires 
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the delivery of three signals by an APC as described previously in Figure 1-1. 
CD4+ T cells commonly referred to as T helper cells (Th) aid the orchestration of 
adaptive immune responses by contributing to the activation of B cells and CD8+ 
T cells and the generation of humoral and cell-mediated immune responses, 
respectively. Initial studies divided a mature CD4+ T cells into two distinct cell 
types referred to as Th1 and Th2 based on their cytokine profile and effector 
functions (Mosmann et al., 1986). Th1 cells provide immunity to a variety of 
intracellular pathogens and produce cytokines such as IFN-γ, lymphotoxin-α (LT-
α) and IL-2 (Mosmann and Coffman, 1989a; Mosmann and Coffman, 1989b; Zhu 
and Paul, 2008). Th1 cells express the transcription factor T-bet and require IFN-
γ and IL-12 for their differentiation (Szabo et al., 2000; Zhu and Paul, 2008). In 
contrast, Th2 cells participate in host defense against extracellular parasites and 
produce cytokines IL-4, IL-5, IL-10, IL-9 and IL-13 (Mosmann and Coffman, 
1989b; Paul and Seder, 1994; Zhu and Paul, 2008). Th1 cells express the 
transcription factor GATA-3 and require IL-4 and IL-2 for differentiation (Kurata et 
al., 1999; Zhu et al., 2001). Extensive studies in the past decade have identified 
2 novel Th subsets, in addition to these classic Th cell subtypes referred to as 
the Tregs and Th17 cells 
  Two distinct types of regulatory T cell have been described: natural T 
regs that arise in the thymus and inducible/adaptive Tregs, that form from 
CD4+CD25-Foxp3- precursors in the periphery (Shevach, 2006; Sakaguchi et al., 
2008; Yamazaki and Steinman, 2009). Regulatory T cells (T-regs), characterized 
by CD25 and Foxp3 expression as well as IL-10 and TGF β, play a critical role in 
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maintenance of self-tolerance, as well as inflammatory responses.  
 The most recent addition to the Th family is the Th17 subset, characterized 
by expression of the transcription factor RORγT and secretion of the cytokine IL-
17 (IL-17a, IL-17f) and IL-22 (Yao et al., 1995; Ivanov et al., 2006). Th17 cells 
function in the clearance of extracellular bacteria and have been implicated in the 
generation of autoimmunity (Weaver et al., 2006; Zhu and Paul, 2008). 
 Lastly CD8+ T cells, also referred to as cytotoxic T lymphocytes (CTLs), 
recognize an antigen in an MHC I-restricted manner. Their prime effector function 
is to detect and kill virally-infected cells, tumor cells and allogenic cells that differ 
in MHC Class I expression. Following its activation, CD8+ T cells employ a series 
of effector mechanisms to achieve immunity. These range from inducing extrinsic 
apoptotic pathways to secretion of perforin and granzymes (Charles A. Janeway, 
2005). 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a member of the family of 
chemicals referred to as halogenated aromatic hydrocarbons (HAHs) (Figure 1-
4). Other members of this family include structurally-related chemicals such as 
dibenzofurans (PCDFs), biphenyl (PCBs) and napthlenes. Amongst these 
chemicals, TCDD is most potent at inducing toxicity and is considered as the 
prototypical HAHs. TCDD is generated and released into the environment as a 
by-product of various industrial activities such as waste incineration, metal 
smelting and burning of chlorine-containing organic chemicals such as plastics  
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Figure 1-4 
 
  
 
 
 
Figure 1-4. Chemical structures of various halogenated aromatic hydrocarbons  
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(Birnbaum, 1994). Additionally, unintentional releases of TCDD into the 
environment have also occurred in the past. For instance, in Seveso an 
explosion released around 300-1200 kg of TCDD into the environment (Dickson 
and Buzik, 1993). TCDD has a molecular weight of 322 and occurs as white 
crystalline solid. A relatively stable compound, TCDD is resistant to breakdown 
by acids, hydrolysis and heat (Webseter and Commoner 1994). However, TCDD 
degrades slowly via photodegradation.  As TCDD and related HAHs are lipophilic 
in nature, they exhibit a propensity to accumulate in fatty tissues and concentrate  
up the food chain from plants to human (Schecter et al., 1994a; Schecter et al., 
1994b). The half-life of TCDD ranges from 7 to over 10 years in humans 
(Aylward et al., 2005). Human exposure to TCDD results from diet, inhalation and 
skin contact. Of these, dietary intake constitutes by far the most important route 
of exposure and accounts for greater than 90% of dioxin exposure via fatty foods 
such as fish and dairy products (Brouwer et al., 1998).  
Aryl hydrocarbon receptor 
  The Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription 
factor belonging to the basic-helix-loop–helix (bHLH) family that mediates the 
toxic manifestations of TCDD and dioxin-like chemicals (Schmidt and Bradfield, 
1996). AhR activation by TCDD has been implicated in the initiation of variety of 
biochemical and toxic responses such as chloracne, developmental and 
reproductive toxicity, carcinogenesis and immune suppression (Bock, 1994). 
Cloning of the AhR revealed important information regarding its structure and 
function (Whitlock, 1993).  In the cytosol, the receptor exists as part of a protein 
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complex with 2 heat shock proteins (hsp90) and XAP 2 (Carver et al., 1994; 
Meyer et al., 1998). In the classical schematic of AhR signaling depicted in 
Figure 1-5, binding of the ligand to the cytosolic receptor induces a 
conformational change leading to dissociation of hsp90 and XAP2 from the 
receptor. This is followed by association of the ligand-bound receptor with the 
helix-loop-helix type nuclear transcription factor, AhR nuclear translocator (Arnt) 
(Reyes et al., 1992). Next, the AhR-ARNT heterodimer binds specific sequences 
termed dioxin responsive elements (DREs) in DNA leading to activation of AhR 
The core consensus sequence within the DRE has been identified as 5’GCGTG-
3’. In addition to Cyp1A1, which harbors nine DREs in its 5’ promoter region, 
other genes involved in growth, differentiation and homeostasis such as c-fos 
and c-jun (Hankinson, 1995; Safe et al., 1998; Nebert et al., 2000). Binding of the 
AhR-ARNT heterodimer to DREs also activates transcription of the Aryl 
hydrocarbon receptor repressor (AhRR), which competes with AhR for formation 
of the heterodimeric complex with Arnt and binding to DREs in target genes. The 
AhRR initiates a feedback mechanism regulating the activity of the AhR (Mimura 
et al., 1999; Watanabe et al., 2001; Karchner et al., 2002). In addition, AhR is 
regulated by protein degradation by ubiquitination mediated by the 26 S 
proteosome (Ma and Baldwin, 2000; Ma et al., 2000).  
Non-DRE mediated AhR signaling: Although binding of activated AhR to DREs 
mediates TCDD toxicity in many physiological systems, an accumulating body of 
evidence shows that activated AhR interacts with other signaling pathways  
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Figure 1-5 
 
 
Figure 1-5. The classical AhR signaling is shown. (1) The prototypical AhR 
ligand TCDD enters into the cell via passive diffusion and binds the AhR with 
high affinity (2) Ligand binding causes dissociation of hsp90 and XAP2 from the 
receptor. (3) Ligand-bound AhR translocates into the nucleus and interacts with 
the AhR nuclear translocator (ARNT). (4) The heterodimeric AhR-ARNT complex 
binds specific DNA sequences known as Dioxin response elements (DREs), 
leading to altered gene transcription of target genes (5) Toxicities are manifested 
in several physiological systems due to AhR activation regulated gene battery 
(Schmidt and Bradfield, 1996; Whitlock, 1999).  
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resulting in cell cycle arrest, inhibition of cellular proliferation, anti-estrogenic 
effects, and modulation of inflammatory responses. Non-DRE mediated AhR 
signaling pathways include interactions between the AhR and retinoblastoma 
protein (Rb), E2F1, Estrogen receptor (ER), MAP kinases and NF-kB members. 
Two distinct models have been proposed to describe the inhibitory effect 
of TCDD on cellular proliferation (Marlowe and Puga, 2005; Puga et al., 2009). 
One model involves AhR-Rb interactions and the other supports the AhR-
mediated induction of cyclin-dependent kinase inhibitors (CDKs) (Puga et al., 
2009). The AhR associates with hypophosphorylated Rb and prevents its 
phosphorylayion in the G1 stage, which represses the E2F-dependent gene 
expression, thus inhibiting progression through the cell cycle (Ge and Elferink, 
1998; Puga et al., 2000). (Puga et al., 2000; Puga et al., 2009). An alternate 
explaination for the induction of G1 arrest by TCDD is the induction of cyclin 
dependent kinase inhibitors such as p27kip. Huang and Elferlink demonstrated in 
TCDD-induced AhR-mediated G1 arrest to be partially regulated by direct AhR 
transcriptional activity in rat hepatoma cells. The same study also provided 
evidence that AhR-mediated G1 arrest required the Arnt protein (Huang and 
Elferink, 2005).  
Another non-DRE event implicated in mediating TCDD toxicity is the 
activation of c-src. Binding of the AhR ligand to the receptor liberates the AhR 
from the Hsp complex leading to activation of c-src. The c-src then activates c-
ras proteins and the MAP kinases pathway, ultimately activating nuclear 
transcription factors such as AP1.  In this context, TCDD induces p38 and 
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ERK1/2 activation in an AhR-independent manner resulting in enhanced TNF-α 
production (Park et al., 2005).  
Similar to the AhR, the Estrogen receptor (ER) is a ligand-activated 
transcription factor and several studies have demonstrated AhR-ER crosstalk. 
Activated AhR exerts antiestrogenic effect by inhibiting ER activity. For instance, 
TCDD represses the induction of ER target genes such as pS2, cathepsin D, c-
fos and cyclin D1 (Beischlag et al., 2008). Several hypothesis emerged to explain 
the repression of these ER target genes. The first explanation proposed 
enhanced E2 metabolism mediated by TCDD-induced expression of Cyp1A1 and 
Cyp1B1 (Spink et al., 1990; Spink et al., 1992). An alternate mechanism 
proposed TCDD-mediated activation of proteosomes leading to increased ER 
degradation (Wormke et al., 2003). Studies have also shown activated AhR to 
redirect ER from ER target genes to AhR target genes, suggesting that AhR 
regulates ERα protein levels and subsequently influence the estrogenic response 
(Matthews et al., 2005). Additionally, recent studies have described the AhR to 
function as a ligand-dependent ubiquitin ligase promoting the degradation of ERα 
and modulating steroid receptor function (Ohtake et al., 2009). 
Recently, evidence has emerged implicating crosstalk between the AhR 
and NF-kB (Ruby et al., 2002; Vogel and Matsumura, 2008). More importantly, 
physical interactions between NF-kB signaling members such as p65 and RelB 
with the AhR contribute to immune suppression and altered inflammatory 
responses (Camacho et al., 2005; Vogel et al., 2007a; Vogel et al., 2007b; Vogel 
and Matsumura, 2008). In vitro AhR activation inhibited p65 nuclear 
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translocation, which was implicated in altered DC survival contributing to immune 
suppression. TCDD-induced modulation in BMDC differentiation was associated 
with decreased RelB levels in BMDCs (Lee et al., 2007). More recently, TCDD-
mediated induction of immune inhibitory enzyme IDO was suggested to require 
both AhR and NF-kB component, RelB (Vogel and Matsumura, 2009). Activation 
of the AhR by TCDD elicits active inflammation in different organs. TCDD-
induced inflammatory responses have been associated with an increased 
production of proinflammatory mediators including TNF-α, IL8, IL-1β and 
cycloxygenase 2 (Cox2)(Vogel and Matsumura, 2009). NF-kB proteins play a 
critical role in regulating inflammatory responses and interact with the AhR. In an 
attempt to elucidate the consequences of RelA/AhR or RelB/AhR interactions on 
inflammatory responses, Vogel et al proposed that activated AhR facilitates the 
function of RelB, both in the induction as well as resolution of inflammation. 
Interaction of the AhR with RelA, on the other hand, dampened the action of 
RelA on inflammatory responses (Vogel and Matsumura, 2009).  Taken together, 
these studies highlight a critical role of the AhR in the regulation of cellular 
inflammation via interactions with the NF-kB signaling pathway. 
TCDD-induced toxicity in animals: Exposure to TCDD generates a spectrum of 
adverse health effects in multiple animals species (Birnbaum and Tuomisto, 
2000). Reported TCDD toxicity, mediated by AhR activation in animals ranges 
from induction of cachexia, disruption of endocrine pathways, chloracne, 
hepatotoxicity, teratogenesis to immune suppression. A cascade of common 
toxic effects of TCDD is observed in all animals following exposure. TCDD-
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induced lethality that occurs in weeks is associated with wasting syndrome, 
characterized by severe weight loss concomitant with reduction in both muscle 
and adipose tissue (Seefeld et al., 1984; Max and Silbergeld, 1987). On a similar 
note, thymic atrophy is also another common manifestation of TCDD toxicity and 
is characterized by lymphocyte depletion in the thymic cortex (Staples et al., 
1998). TCDD-induced toxicity is also associated with severe a skin condition 
characterized by hyperkeratotic and hyperproliferative skin response known as 
Chloracne (Birnbaum and Tuomisto, 2000). This acute skin condition has been 
reported in cows, horses, ears of rabbit and also on the skin of hairless mice 
(Birnbaum and Tuomisto, 2000). Hepatotoxicity is reported in rats and rabbits 
following TCDD exposure.  Reproductive effects from TCDD exposure have been 
documented in mice, rats and monkeys where TCDD is demonstrated to reduce 
litter size, fertility and uterine weights (Kociba et al., 1976; Barsotti et al., 1979; 
Umbreit et al., 1987). TCDD exposure has been associated with induction of 
developmental syndrome in mice characterized by fetal thymic atrophy, 
hydronephrosis and cleft palate (Couture et al., 1990a; Couture et al., 1990b; 
Birnbaum and Tuomisto, 2000). In chickens, TCDD affects the cardiovascular 
system. Additionally, TCDD also targets the nervous system; however, 
mechanisms underlying neurotoxic effects of TCDD remain poorly investigated 
(Birnbaum and Tuomisto, 2000). Studies have also identified TCDD as a 
complete carcinogen in lab animals. Exposure to TCDD at increasing doses 
induces cancer in experimental animals and is associated with development of 
tumors in the liver, thyroid, respiratory tract and other organs. 
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The severity of TCDD toxicity is dependent on multiple factors such as the 
animal species, strain, age and gender (Neubert, 1997). Differential sensitivity of 
animal species to TCDD is attributed to polymorphisms in the Ah locus (Takashi 
Moriguchi 2003). For example, a 10-fold difference in susceptibility to TCDD has 
been reported between C57Bl/6 (sensitive) and DBA/2 (resistant) strain of mice 
(Dolwick et al., 1993; Ema et al., 1994a; Ema et al., 1994b). C57Bl/6 and Balb/c 
express the dominant responsive allele, Ahrb-1 and Ahrb-2, respectively when 
compared to the less responsive strain DBA/2 bearing the recessive non-
responsive allele designated Ahrd (Poland and Grover 1990). Similarly, Long 
Evans (sensitive) and Han/Wistar rats (resistant) differ in a magnitude of >1000 
fold in terms of their susceptibility to dioxins due to a mutation in the Trans 
activation domain of the AhR (Takashi Moriguchi 2003).  
AhR knockout, mutant and transgenic mice: Generation of AhR knockout and 
mutant mice has played an instrumental role in dissecting the AhR-mediated 
toxicities from those arising from alternative pathways (Fernandez-Salguero et 
al., 1995; Schmidt et al., 1996). AhR knockout mice (AhR-/-) were first created 
using gene targeting strategies that inactivated the murine AhR gene by 
homologous recombination (Schmidt et al., 1996). The resulting AhR-/- mice were 
viable, yet displayed developmental defects in the liver (Schmidt et al., 1996). 
Furthermore, AhR-/- mice were protected against a spectrum of TCDD toxicities 
ranging from hepatomegaly, thymus atrophy and also immunotoxicity 
(Fernandez-Salguero et al., 1995; Thurmond et al., 2000). Studies have 
demonstrated a lack of TCDD effect in AhR KO even at a high dose TCDD 
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(2000µg/kg). Also, no TCDD-induced lesions were observed in the kidney, heart, 
pancreas, spleen, lymph nodes and uterus in AhR-/- mice following TCDD 
exposure, suggesting that the pathologic changes induced by TCDD were AhR 
dependent.  
Mice harboring a mutation in the AhR nuclear localization (AhRnls/nls) were 
also generated to determine whether nuclear DRE-mediated events are essential 
for the generation of toxic and developmental effects following AhR activation 
(Bunger et al., 2003).  These mice express the mutant AhR that is capable of 
ligand binding but is unable to translocate to the nucleus and bind the DREs. 
AhRnls/nls mice also display defects in liver development and are resistant to 
TCDD-induced thymic involution, hepatomegaly and cleft palate formation 
(Bunger et al., 2003).  Bradfield et al., subsequently developed AhR mutant mice 
designated AhRdbd/dbd that are capable of herterodimerizing with ARNT, but 
incapable of binding DREs (Bunger 2008). Thus, despite nuclear translocation, 
AhRdbd/dbd mice displayed no manifestation of TCDD-induced toxic effects 
including, cleft palate, hydronephrosis, hepatomegaly and thymic involution 
(Perdew, 2008). To assess the importance of ARNT heterodimerization events in 
dioxin-induced toxicities, Walisser et al., generated a hypomorphic or low-
expressing Arnt allele, designated Arnt fxneo. Similar to the AhR-/- mice, ARNT 
hypomorphs displayed a patent ductus venousus establishing that ARNT 
heterodimerization constituted an essential aspect of AhR developmental 
signaling.  
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A major manifestation of TCDD immunotoxcitiy in animals is thymic 
involution, characterized by decreased CD4+CD8+ T cell numbers and skewing of 
thymocyte differentiation to single positive CD8+T cells(Staples et al., 1998; 
Nohara et al., 2000). To understand the role of AhR in T cells and its contribution 
in TCDD-induced immuotoxicity, Nohara and colleagues generated transgenic 
mice that expressed a constitutively active mutant of AhR (CA-AhR) in T lineage 
cells (Nohara et al., 2005). These transgenic mice displayed decreased numbers 
of thymocytes and an increased percentage of CD8+ T cells, suggesting that AhR 
activation in T lineage cell was directly responsible for the thymocyte loss and 
altered differentiation.  
Lastly, to assess the functioning of human AhR (hAhR), Moriguchi et al., 
created AhR-humanized mice, possessing hAHR instead of mouse AhR. 
Decreased responsiveness to TCDD was observed in mice harboring hAhR as 
compared to DBA/2 AhR. For instance, TCDD induced embryonic 
hydronephrosis but no cleft palate in maternally-exposed homozygous hAHR 
fetuses. Creation of these transgenic mice provides a novel tool not only to better 
understand the function of the human AhR but also predict TCDD toxicities in 
humans (Moriguchi et al., 2003). 
TCDD toxicity in humans: Much of what is known today about TCDD toxicity 
comes from populations accidentally exposed to TCDD, workers occupationally 
exposed to TCDD or populations living close to toxic waste dumps. Since the first 
reported incidence of human exposure to TCDD due to a trichlorophenol reactor 
explosion in Nitro, West Virginia, several other accidental exposures have been 
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reported. These global incidents of human exposure include but are not limited to 
PCB-contaminated rice oil consumption in Japan and Taiwan, an explosion at a 
trichlorophenol manufacturing plant in Seveso, Italy, and contamination of a 
resident community with tainted waste oil in Missouri (Sweeney and Mocarelli, 
2000; Kerkvliet, 2002). Because TCDD has a long half-life in humans and 
accumulates at a high rate in the body, manifestation of TCDD-induced toxicities 
occurs after prolonged low level, daily exposure. Thus, human exposure to dioxin 
is associated with chronic, long-term adverse health effects. Studies have linked 
TCDD exposure with symptoms such as chloracne, hyper pigmentation, 
metabolic alteration, weight loss, immune suppression, neuropathy, endocrine 
dysfunction and perturbations in the gastrointestinal systems.  For example, 
temporary hepatomegaly observed in individuals exposed to dioxin in the Seveso 
incident was associated with no concomitant elevation in hepatic enzymes 
(Sweeney and Mocarelli, 2000). Acute exposure to TCDD is documented to 
transiently upregulate liver enzymes such as AST, ALT and gamma glutamyl 
transferase (GGT). No association of TCDD to altering cholesterol levels was 
found in studies that involved Seveso residents and Vietnam veterans (Sweeney 
and Mocarelli, 2000). Similarly, no effect on thyroid function was demonstrated in 
studies involving production workers (Suskind and Hertzberg, 1984; Ott et al., 
1994; Calvert et al., 1999).  
In stark contrast to the variable reports on the non-cancer toxic endpoints 
of dioxins, the carcinogenic potential of TCDD is well accepted within the 
scientific community. Epidemiological studies have linked TCDD exposure with 
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soft-tissue sarcomas, respiratory system tumors and other cancers including Non 
Hogkins lymphoma (NHL), in populations exposed accidentally to high 
concentrations of TCDD (Fingerhut et al., 1991). Based on carcinogenicity data 
in animal models and epidemiological data, TCDD is listed as a human 
carcinogen by the International Agency for Research on Cancer (IARC) (IARC, 
1997). However, the mechanisms underlying the human carcinogenic potential of 
TCDD need further investigation (Cole et al., 2003; Steenland et al., 2004). 
In addition, immunological effects of dioxin exposure are also documented 
in humans. While some studies have described no clinical signs of immune 
suppression in exposed cohorts, others have documented alterations in serum 
IgA, IgG and lymphocyte populations and antinuclear antibodies in exposed 
individuals (Ott et al., 1994). For instance a study conducted on 40 Missouri 
residents whose adipose TCDD levels ranged from 20pg/g to over 430 pg/g, no 
clinical evidence of immune suppression was detected (Webb et al., 1989). 
Children exposed to TCDD in the Seveso accident, revealed increased serum 
complement levels, peripheral blood lymphocytes and increased 
lymphoproliferative responses with no adverse clinical effects (Tognoni and 
Bonaccorsi 1982).  Increased serum IgA levels were detected in US Air Force 
personnel exposed to herbicides (Wolfe et al., 1990). An assessment of 
immunologic spectrum of the Vietnam War veterans exposed to Agent Orange 
contaminated with TCDD showed decreased plasma IgG and increased IgE 
levels in the veterans compared to age-matched healthy controls. Following 
activation of their peripheral blood mononuclear cells with polyclonal T cell 
 28 
activators, decreased levels of IFN-γ and increased levels of IL-4 and IL-10 were 
detected in the veteran group (Kim et al., 2003). Taken together, these studies 
demonstrate that TCDD exposure results in dysregulated B and T cell responses 
eventually leading to perturbation of immune homeostasis.  
Using an in vitro model, several investigators have examined the direct 
toxic effects of TCDD on various human leukocyte populations. Neubert et al 
reported direct effects of TCDD on T cells and B cell proliferation. Both the 
percentage and the number of CD4+ and B cells activated with PWM decreased 
following activation with 10-12 and 10-14 M, TCDD concentration respectively 
(Neubert et al., 1991). Subsequently, Lang et al., reported no direct effect of 
TCDD on human lymphocytes treated with 10-7-10-14 M TCDD in the absence of 
stimulation with PMW or anti-CD3. An increase in Cyp1A1 activity, with no effect 
on lymphocyte proliferation led the authors to conclude that the immunotoxic 
effects do not correlate with Cyp1A1 induction (Lang et al., 1994). Additionally, a 
study assessing Cyp1A1 induction in human blood lymphocytes in 10 non-
smoking females showed that concentrations of TCDD necessary to elicit in vitro 
induction of Cyp1A1 were much higher than human blood levels in vivo. These 
studies concluded that the measurement of Cyp1A1 gene expression levels was 
not a suitable marker for assessing human immunotoxicity (van Duursen et al., 
2005).  
Taken together, a defined relationship between exposure and impaired 
immune status remains unestablished. However, with such varying reports 
regarding the effects of TCDD on human health, continued surveillance of 
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exposed populations and research is warranted to fully understand the long-term 
effects of dioxin exposure. The lack of consistent effects on humans have been 
attributed to several factors such as lack of proper exposure documentation, 
small study populations, genetic variation between human populations and also 
insensitive immunological assays. Therefore, future prospective research 
examining the immunotoxic effects of TCDD is warranted. Understanding the 
mechanism of action of TCDD in laboratory animals first, will provide a stronger 
platform for assessing human health risks. Additionally, it will also allow 
identification and development of a novel biomarker that can be applied to 
human studies. Nevertheless, considering the spectrum of adverse health effects 
generated by TCDD, industries have taken measures to minimize release of 
dioxin into the environment. 
Animal studies have shown that TCDD toxicities are mediated via the Aryl 
hydrocarbon receptor (AhR). Additional studies are needed to completely 
understand the physiological role of human AhR as well as its role in TCDD 
toxicity. Additionally, using laboratory animals, there is a continuous effort to 
elucidate AhR-regulated pathways in mediating TCDD toxicities as discussed in 
the following sections.  
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TCDD Immunotoxicity 
The immune system has been identified as a sensitive target of TCDD 
(Luster et al., 1989).  Exposure of laboratory rodents to very low doses of TCDD 
(1<µg/kg body weight) suppresses the generation of adaptive immunity and 
increases the susceptibility to infectious diseases (Kerkvliet et al., 1994). TCDD 
primarily exerts its toxic effects by binding and activation of the AhR. The AhR is 
expressed in several immune cell populations including macrophages, T cells 
and B cells (Crawford et al., 1997). Both the innate and adaptive immune 
systems are sensitive to AhR activation by TCDD.  
Effects of TCDD on the innate immune system: AhR activation by TCDD 
affects innate cell populations such as neutrophils, natural killer cells, 
macrophages and DCs (Kerkvliet, 2009). In various experimental models, TCDD-
treatment has been linked with neutrophilia. Injection of caesin or sheep RBCs in 
TCDD-treated mice resulted in peritoneal and pulmonary neutrophilia 
(Ackermann et al., 1989; Kerkvliet and Oughton, 1993). Neutrophilia was also 
reported in the spleen in allograft response to P815 tumor cells and in the lung 
following flu infection (Choi et al., 2003; Teske et al., 2005). In the context of flu 
infection, neutrophilia occurred independent of classical chemoattracants such as 
macrophage inflammatory protein (MIP)-Ia, MIP-2, IL-6, lipopolysaacharide-
induced CXC chemokine (LIX) or C5a, but rather AhR expressing cells in the 
lung were implicated (Teske et al., 2008). Although, the mechanisms underlying 
TCDD-induced neutrophila are not completely understood, AhR has been 
demonstrated to be an essential component. Several conflicting studies 
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documented the effects of AhR activation in NK cells. For example, the cytolytic 
activity of NK cells has been shown to be increased, decreased or unaffected 
(Lawrence 2007). Adverse effects of AhR activation on macrophages have 
similarly been documented. Although AhR activation does not influence either 
macrophage phagocytosis, oxidative burst, or tumor cytolytic function, increased 
production of proinflammatory cytokines such as TNF-α and IL-1 have been 
identified as mechanism underlying TCDD-induced inflammation (Moos et al., 
1997) (Lawrence 2007). This increase in TNF-α production in human 
macrophages was found to be dependent on the AhR-EGFR-Erk pathway 
(Cheon et al., 2007) Moreover, AhR activation in macrophages induces 
transcriptional gene expression changes via either the CaM kinase or the AhR-
RelB pathway. TCDD-treatment upregulates mRNA levels for Cyp1b1, IL1b, IL8, 
Ccl1, β7-integrin and Ahrr in primary human macrophages, in a CaM kinase-
dependent manner (Monteiro et al., 2008).  In other studies, AhR-RelB 
interactions were implicated in TCDD-induced expression of B cells activating 
factor (Baff), B cell chemoattractant (Blc), chemokine (C-Cmotif) ligand 1 (Ccl1) 
and Interferon γ response factor (Ifr) in a human macrophage cell line (Vogel et 
al., 2007b). Interestingly, these AhR/RelB interactions did not require ARNT 
demonstrating the role of non-DRE-mediated effects on TCDD induced 
inflammatory responses. 
DCs express the AhR constitutively and several studies suggest that 
defects in DCs following AhR activation contribute to immune suppression. 
Decreased numbers of splenic DCs, as well as increased expression of MHC II, 
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CD54, CD40, and CD24 was observed in TCDD-treated mice (Vorderstrasse and 
Kerkvliet, 2001). DCs from TCDD-treated mice exhibited higher T cell 
proliferative response in a mixed lymphocyte reaction and also produced higher 
levels of IL-12. Despite this, TCDD did not alter the ability of DCs to phagocytose 
latex beads or present Keyhole Limpet Hemocyanin (KLH) to KLH-specific T cells 
suggesting that processing and presentation function were unaffected by TCDD 
(Vorderstrasse et al., 2003). Later studies also demonstrated the sensitivity of in 
vitro generated DCs to TCDD. TCDD enhanced TNF-α-induced DC maturation 
and Fas-mediated apoptotic death (Ruby et al., 2005). Microarray analysis 
revealed that TCDD increased expression of several genes including Fadd, 
Dff40, Ox40l and caspase 9 in purified DCs, suggesting their involvement in 
induction of DC apoptosis following AhR activation (Ruby et al., 2005). 
Mechanistically, several investigators have implicated non-DRE mediated events 
in the generation of DC dysfunction following TCDD exposure. In this context, 
interactions of the AhR with NF-kB signaling pathway have been reported as a 
mechanism underlying TCDD-induced alterations in DCs. TCDD was shown to 
suppress TNF-α- and CD40-induced NF-kB/Rel activation in vitro (Ruby et al., 
2002). In a separate study, Lee et al., demonstrated TCDD altered the 
differentiation of bone marrow-derived dendritic cells (BMDCs), an effect that was 
attributed to down regulation of RelB (Lee et al., 2007). These studies suggest 
that TCDD-induced alterations in NF-kB signaling contributes to defects in DCs, 
leading to immune suppression. 
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Effects on adaptive immunity: AhR activation by TCDD induces profound 
suppression of the adaptive immune system. Both B and T cells constitutively 
express low levels of AhR and require activation to enhance its expression 
(Lawrence et al., 1996; Crawford et al., 1997; Marcus et al., 1998)  
B cells: Evidence that B cells are directly affected by TCDD is provided by 
studies conducted by several labs that show modulation of B cell responses in 
vitro by TCDD. Kramer et al., linked TCDD-induced kinase activity and 
modulation of intracellular Ca2+ levels in B cell to altered B cell responses 
(Kramer et al., 1987). Studies by Luster et al demonstrated for the first time that 
TCDD inhibits B cell differentiation into plasma cells in response to TNP-LPS 
(Luster et al., 1988). TCDD-induced alterations in Ca2+ levels was also linked 
with TCDD-induced suppression of surface Ig, but not CD40-mediated antibody 
production (Karras et al., 1996). In other studies, TCDD inhibited µ gene 
expression and IgM secretion in a CH12.LX B-cell line (Sulentic 2000). This 
inhibition of LPS-stimulated IgM secretion was not noted in the BCL-1 B-cell line 
that lacks the AhR (Sulentic 1998). Decreased levels of the human B cell 
differentiation marker, CD19, following TCDD exposure were linked to 
competition between the AhR and B-lineage–specific activator protein (BSAP) 
(Masten and Shiverick, 1995). The suppression of CD19, a key molecule 
involved in signaling through the BCR, could underlie suppression of antibody 
responses by TCDD (Kerkvliet, 2002).  
CD4+ and CD8+ T cells: TCDD triggers thymic atrophy and suppresses the 
generation of antigen-specific T cell responses in vivo (Kerkvliet, 2002). TCDD 
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decreased both CD4+ and CD8+ T cell function, however debate continues as to 
whether T cells are direct or indirect targets of TCDD. While some reports 
suggest that T cells are not directly affected by TCDD due to lack of AhR binding 
to the consensus DRE in T cells, (Lawrence et al., 1996), other investigators 
suggest a direct AhR-dependent effect of TCDD in both CD4+ and CD8+ T cells 
(Kerkvliet et al., 2002). CD4+ T cell differentiate into Th17, Th1, Th2 or Treg 
subsets. The differentiation into each of these specific subsets is dependent on 
the expression of transcription factors such as ROR-γT, GATA and Foxp3 that 
are shown to express multiple DREs, respectively (Kerkvliet, 2009). This 
observation suggests that the AhR may play a prominent role in specifying T cell 
differentiation. In a murine graft-versus-host (GvH) model, TCDD promotes Treg 
differentiation in donor CD4+ T cells, as defined by their increased expression of 
CD25, CTLA-4 and GITR (Funatake et al., 2005). The same study also 
demonstrated that TCDD did not merely expand a natural Treg population in the 
donor cells as depletion of natural Tregs from donor population prior to injection 
into F1 host did not affect the AhR-mediated generation of Tregs (Funatake et 
al., 2005). Interestingly, Foxp3 expression was not detected in AhR-dependent 
CD4+CD25+ cells, highlighting the AhR as a novel transcription factor for adaptive 
Tregs. Subsequent studies demonstrated AhR-dependent modulation of 
numerous genes in TCDD-Tregs including TGFβ-3, CCr4, Bcl3, CTLA-4, IL-10, 
GATA-3, Icos, CD28 and genes involved in IL-12 signaling pathway. 
Downregulated genes included Tnfsf4 (OX40-L), IL13ra, CD86, Bcl6, IL5, NFkb1 
and Ccl5 (Marshall et al., 2008). Recently, ligand-specific AhR activation in T 
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cells has been shown to generate Tregs or Th17 cells. These studies 
demonstrated AhR activation by TCDD or natural AhR ligand formylindolo[3,2-
b]carbazole (FICZ) to generate Treg or Th17 cells, respectively (Quintana et al., 
2008; Veldhoen et al., 2008). Cumulatively, these findings suggest that AhR 
activation during CD4+ T cell differentiation alters gene expression contributing to 
altered T cell fate. 
In addition to studies on CD4+ T cells, several investigators have 
assessed the effects of AhR activation on CD8+ T cell function using the P815 
tumor allograft model and the influenza model (Kerkvliet, 2002; Lawrence et al., 
2006).  Using the P815 tumor model, Kerkvliet et al., showed that TCDD did not 
affect the normal expansion and activation of CD8+ T cells, but affected their 
ability to differentiate into functional cytotoxic T lymphocytes (CTLs). The CD8+ T 
cells in TCDD-treated mice initially displayed normal production of IL-2 and IFNγ 
that diminished on day 5-6 as compared to vehicle-treated control mice (Kerkvliet 
et al., 1996). Various hypothesis emerged to describe the observed suppression 
of CTL response such as the induction of TCDD-induced apoptosis and/or 
anergy of CD8+ T cells (Prell and Kerkvliet, 1997; Prell et al., 2000). Suppression 
of the CTL response in this model was also linked to CD4+ T cells. Since TCDD-
treated mice produced higher IL-2 on day 4 and 5 of the P815 response, it was 
hypothesized that TCDD-induced excess production of IL-2 by CD4+ T cells 
leading to their premature deletion. Such deletion deprived the CD8+ T cells of 
cognate CD4+ T cell help, preventing CTL expansion (Kerkvliet, 2002). Further 
support for this hypothesis arrived from studies by Jeon and Esser demonstrating 
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the existence of 3 DREs in the distal region of mouse IL 2 promoter, suggesting 
that TCDD-induced excess IL-2 production by CD4+ T may lead to activation-
induced cell death (Jeon and Esser, 2000).  
In addition to the P815 tumor model, CD8+ T cell function following AhR 
activation has been assessed using a murine model of influenza A infection. 
TCDD suppressed clonal expansion and differentiation of influenza virus-specific 
CD8+ T cells during primary infection, decreased the number of virus-specific 
CD8+ T cells secreting IFNγ, and decreased the number but not the response of 
virus-specific memory CD8+ T cells (Head and Lawrence, 2009). TCDD 
treatment also decreased the number of CD4+ T cells required for antibody 
isotype switching and maintenance of anti-viral CD8+ T cell memory. 
Interestingly, recent reports have linked AhR activation in CD8+ T cells with CD8+ 
Treg development as defined by increased CD25 expression and suppressed 
cytolytic activity (Funatake et al., 2008). However, AhR expression in CD4+ T 
cells was essential for the generation of CD8+ T regs Overall, these results 
suggest that AhR-mediated events impact anti-viral immunity, decreasing the 
priming of CD8+ T cells. 
AhR activation by ligands other than TCDD: As previously described, the AhR 
mediates the toxic manifestation of TCDD and TCDD-like chemicals found in the 
environment. However, the AhR is an evolutionarily-conserved receptor 
suggesting it’s physiological function may extend beyond mediating toxicities of 
environmental pollutants such as TCDD. Corroborating this idea are studies 
describing AhR to negatively regulate LPS-induced inflammatory responses in 
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macrophages, demonstrating its physiologic role in inflammation (Kimura et al., 
2009). More recently, numerous novel natural AhR ligands ranging from dietary 
components such as flavones to bilirubin have been described (Table1-2). 
Although several investigators have attempted to assess the impact of AhR 
activation by natural ligands, very little is known about the character of these 
natural AhR ligands and their role in AhR signaling. Characterizing the effects of 
natural AhR ligands and their specific mechanisms in immune cells may provide 
insights into the physiological functions of the AhR receptor in the immune 
system and help devise strategies by which AhR activation can be therapeutically 
exploited. 
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Table 1-2: The diverse range of natural and non-TCDD AhR ligands. 
 
Natural and non-TCDD AhR ligands 
Parent Category Examples Function 
α-napthaflavone • AhR antagonist (Zhang et al., 
2003) 
β-napthoflavone • AhR agonist  (Zhang et al., 2003) 
Flavones 
Genistein • Suppresses immune and 
inflammatory responses 
(Verdrengh et al., 2003) 
• Decreases UV-induced 
inflammation(Widyarini et al., 
2001) 
2-(1’H-indole-3’-
carbonyl)-thiazole-4-
carboxylic acid methyl 
ester (ITE) 
• AhR agonist but does does not 
induce TCDD-induced toxicity 
such as cleft palate. 
Indole-containing 
molecules 
6-formylindolo(3,2-b) 
carbazole 
• Induces Th17 differentiation 
(Veldhoen et al., 2008) 
• Enhances EAE development 
M50367 • AhR receptor agonist (Morales et 
al., 2008) 
M50354 • Suppresses Th2 differentitaion 
(Negishi et al., 2005) 
VAF347 • Anti-inflammatory and anti-
allergenic(Hauben et al., 2008; 
Lawrence et al., 2008) 
Benzoimidazole 
derivatives 
VAG539 • Inhibits rejection of pancreatic islet 
allografts in Balb/c mice 
associated with increased 
frequency and survival of CD4+ 
CD25+Foxp3 T-reg 
phenotype.(Hauben et al., 2008) 
Bilirubin  • Inhibits CD4 T cell function in 
vitro(Liu et al., 2008; Kerkvliet, 
2009). 
• Suppresses EAE development in 
vivo(Liu et al., 2008) 
Leflunamide  • Anti-inflammatory compound used 
in treatment of rheumatoid 
arthritis.(Herrmann et al., 2000) 
• Metabolized into A771762, that 
inhibits denovo pyrimidine 
synthesis and inhibits T cell 
proliferation (Williamson et al., 
1995; Dimitrova et al., 2002) 
• Induces antigen-specific regulatory 
CD4+ and CD8+ T cells 
(Weigmann et al., 2006). 
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HYPOTHESIS 
Dendritic cells (DCs) are the primary APCs involved in the activation of 
naïve T cells and constitutively express the AhR receptor. DCs are sensitive to 
TCDD; however limited information exists on the effects of AhR activation in 
these cells. Defects in T cell activation following AhR activation have been linked 
to AhR-induced defects in DCs. Previous studies demonstrated loss of splenic 
DCs following TCDD-exposure, as well as increased expression of CD54, MHC II 
and CD40 (Vorderstrasse and Kerkvliet, 2001; Vorderstrasse et al., 2003). 
Interestingly, TCDD did not modulate the ability of DCs to process and present 
antigen (Vorderstrasse et al., 2003). Ruby et al., also reported direct effects of 
TCDD on the maturation and survival of murine, GM-CSF-derived BMDCs.  In 
these studies, TNF-α-induced DC maturation and Fas-mediated apoptotic death 
was enhanced by TCDD (Ruby et al., 2005). Preliminary data from our laboratory 
demonstrated AhR activation by TCDD enhanced DC deletion and generation of 
defective T cell responses. TCDD-mediated loss or deletion of antigen-bearing 
DCs in the lymph node of mice that received Ag-specific OT II cells was found to 
be dependent on AhR expression. In addition, DCs from TCDD-treated mice 
produced less IL-12 and IL-18 compared to vehicle-treated mice. Cumulatively, 
these studies demonstrate that DCs are direct targets of TCDD-induced toxicity 
mediated by AhR activation. These TCDD-induced changes in DCs may 
dysregulate an immune response and underlie immune suppression. 
Because DCs play a key role in generation of successful T cell-mediated 
immunity, clearly defining the potential effects of persistent environmental 
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pollutants such as TCDD on their fate and function is important.  The overall goal 
purpose of this study is to provide in depth characterization of the consequences 
of AhR activation on murine DCs.  The central hypothesis is that AhR activation 
modulates DC fate and function, thereby contributing to TCDD-mediated 
immune suppression. The following specific aims using in vivo and in vitro 
approaches were designed to address this hypothesis: 
Aim 1. To evaluate the effects of TCDD on the fate of naïve DCs. (Chapter 2) 
Previous studies conducted by Vorderstrasse and coworkers provided an initial 
characterization of the effects of TCDD on murine DCs.  In these studies, TCDD 
induced a decrease in CD11c+ DCs and also affected the expression of key 
surface costimulatory molecules in an AhR-mediated fashion (Vorderstrasse and 
Kerkvliet, 2001; Vorderstrasse et al., 2003). In a separate study, TCDD was 
reported to enhance the TNF-α-induced maturation of BMDCs rendering them 
more sensitive to CD95-mediated apoptosis (Ruby et al., 2005). However, the 
effects of TCDD on specific murine DC subsets remains to be defined and the 
mechanisms underlying the loss of naïve splenic DCs remain to be elucidated. 
We hypothesized that TCDD alters DC homeostasis, resulting in the loss of 
DCs in naïve mice. 
To perform this investigation, C57Bl/6 mice were gavaged with vehicle or 
an immunosuppressive dose of TCDD (15µg/kg). Spleen and lymph nodes were 
harvested and assessed for TCDD-induced modulation of DC differentiation 
markers. Furthermore, effects of TCDD on the fate of functionally distinct splenic 
CD11chigh DC subsets, the CD11chigh CD8α+ DEC205+ and the CD11chigh CD8α– 
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33D1+ cells were assessed. Since TCDD selectively, decreased splenic 
CD11chigh DC, we evaluated the role of apoptotic and/or migratory events in 
mediating this loss of splenic CD11chigh DCs. The extrinsic apoptotic pathway 
was assessed using Fas deficient (lpr/lpr) and FasL deficient (gld/gld) deficient 
mice. Alternatively, TCDD-induced migration was evaluated via induction of 
CCR7, a prominent chemokine receptor involved in the migration and trafficking 
of DCs.  
Aim 2.  To examine the effects of TCDD on the innate and adaptive immune 
function of murine BMDCs and assess whether the effects are mediated 
exclusively via Dioxin response elements (DREs) (Chapter 3) 
Dendritic cells are hematopoietically-derived cells which can be generated in vitro 
from murine bone marrow cells using the growth factor, GM-CSF. Generation of 
bone marrow-derived dendritic cells (BMDCs) allows a rapid, convenient 
assessment of DCs following exposure to TCDD. Many investigators have 
attempted to recapitulate the observed in vivo effects of TCDD exposure on DCs 
in an in vitro setting. For instance, studies conducted by Ruby et al., showed that 
TCDD-treatment of BMDCs enhanced TNF-α-induced maturation, and also 
augmented the CD95-mediated death of BMDCs (Ruby et al., 2004). More 
recently, Lee et al., demonstrated TCDD-induced down regulation of RelB mRNA 
levels in GM-CSF derived BMDCs (conventional DCs) (Lee et al., 2007). 
However, the effects of TCDD on a homogenous, pure population of DCs 
remains to be characterized. Additionally, several investigators have linked AhR 
activation by TCDD with induction of Tregs and Treg inducing mediators such as 
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IDO1, IDO2 and TGF-β3.  Despite these studies, it remains to be determined 
whether TCDD affects the normal development and function of DCs. Additionally, 
it is unknown whether AhR activation induces regulatory DCs that could 
contribute to Treg generation.  Under the second specific aim TCDD-induced 
phenotypic and functional alterations in conventional DCs (GM-CSF derived) will 
be examined. We hypothesize that TCDD alters BMDC differentiation and 
generates a regulatory phenotype. 
 To perform this study, inflammatory BMDCs from C57Bl/6 mice were 
generated using GM-CSF, in the presence of vehicle (DMSO) or TCDD. TCDD-
induced modulation in BMDC differentiation markers, antigen-uptake and TLR 
responsiveness was assessed. Furthermore, NF-kB activation profile in these 
BMDC cultures was assessed using TransAM NF-κB colorimetric assays. The 
functional ability of vehicle-or TCDD-treated BMDCs to interact with CD4+ T cells 
in an antigen-specific fashion and influence the development of an adaptive 
immune response was tested using an adoptive transfer model. To delineate the 
role of the activated AhR in the fate and development of conventional DCs in 
vitro, we generated BMDCs from the bone marrow of AhR-/- and AhRnls/nls and 
AhRdbd/dbd mice. Bone marrow cells from these mutant mice were cultured in 
presence of GM-CSF and vehicle or TCDD (10nM) for 6 days. Non-adherent 
cells were harvested and evaluated for TCDD effects on phenotypic DC markers. 
Alteration in DC phenotype was compared to naïve C57Bl/6 mice expressing 
high-affinity AhR. Additionally, mRNA levels of suppressive T-reg inducing 
mediators such as Indoleamine 2,3-dioxygenase (IDO) and TGF-β3 were 
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evaluated in BMDCs. 
Aim 3: To examine whether AhR-activated BMDCs contribute to the 
generation of regulatory T cells (Chapter 4) Results from the previous specific 
aim 2 demonstrated TCDD-induced regulatory phenotype in DCs characterized 
by increased IDO1, IDO2 and TGF-β3 mRNA levels. We therefore, assessed the 
effects of these regulatory DCs on the generation of T regs. We hypothesized 
that TCDD-treated BMDCs, displaying a regulatory phenotype induce 
adaptive Tregs.  
To perform this investigation, ova-peptide loaded, vehicle- or TCDD –
treated BMDCs were cocultured with antigen-specific CD4+CD25- T cells. On day 
4, cells were harvested and evaluated. Additionally, an adoptive transfer model 
examining the role of LPS-activated TCDD BMDCs in suppressing T cell 
activation was employed. 
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ABSTRACT 
  The environmental contaminant, TCDD (dioxin), causes immune 
suppression via activation of the Aryl hydrocarbon receptor (AhR). Dendritic cells 
(DCs), the professional antigen-presenting cells in the immune system, are 
adversely affected by TCDD. We hypothesize that TCDD alters DC homeostasis, 
resulting in DC loss in naïve mice. To test this hypothesis, C57Bl/6 mice were 
gavaged with either vehicle or TCDD (15 µg/kg). Consistent with previous 
reports, TCDD exposure decreased the frequency and number of splenic 
CD11chigh DCs on day 7, when compared to vehicle. TCDD increased the 
expression of CD86 and CD54, while decreasing the frequency of CD11a and 
MHC Class II on the splenic CD11chigh DCs. The frequency of CD40 on 
CD11chigh DCs was increased by TCDD. Moreover, TCDD selectively decreased 
the CD11chighCD8α-33D1+ splenic DCs subset specialized at activating CD4+ T 
cells but did not affect the regulatory CD11chighCD8α+DEC205+ splenic DC 
subset. TCDD did not alter the number and frequency of CD11clow splenic DCs, 
but decreased their MHC II and CD11a expression. The splenic CD11chigh DC 
loss was independent of Fas-mediated apoptosis. Furthermore, CD11chigh DCs 
displayed no apoptosis as defined by Annexin V/7-AAD staining. Instead, 
increased CCR7 expression on CD11chigh DCs suggested involvement of a 
migratory event. Popliteal and brachial lymph node  (PBLNs) CD11c+ cells 
displayed elevated levels of MHC II and CD40 but not DC loss following TCDD 
exposure. Collectively, this study demonstrates the presence of a TCDD-
 
 
 60 
sensitive splenic DC subpopulation in naïve mice, suggesting that TCDD may 
induce suppression of T cell-mediated immunity by disrupting DC homeostasis. 
 
Key words: Aryl hydrocarbon receptor; dendritic cells; immunosuppression; 
TCDD; apoptosis; CCR7 
 
Abbreviations:  AhR, Aryl hydrocarbon receptor; cells; Ag, antigen; APC, 
antigen presenting cell; CCR7, Chemokine receptor 7; CCL19, EBI1 ligand 
chemokine/MIP-3β; CCL21, secondary lymphoid tissue chemokine 
[SLC]/6Ckine; DCs, dendritic cells; IKDC, Interferon producing killer dendritic 
cell; PAMPs, pathogen-associated molecular patterns; PBLN, popliteal and 
brachial lymph nodes; pDC, plasmacytoid dendritic cell; TCDD, 2,3,7,8 
tetrachlorodibenzo-p-dioxin. 
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INTRODUCTION  
The immune system has been identified as a sensitive target of 2,3,7,8 
tetrachlorodibenzo-p-dioxin (TCDD) (Luster et al., 1989).  Exposure of laboratory 
rodents to very low doses of TCDD suppresses the generation of adaptive 
immunity and increases the susceptibility to infectious diseases (Kerkvliet and 
Burleson, 1994). TCDD primarily exerts its toxic effects by binding and activation 
of the Aryl hydrocarbon receptor (AhR) (Fernandez-Salguero et al., 1996; 
Perdew, 2008). 
   Dendritic cells (DC) are the most potent antigen presenting cells and the 
primary immune cells responsible for the activation of naive T cells.  DCs 
populate most tissues in mice and can be identified by the expression of the 
integrin, CD11c. DCs progress through multiple differentiation stages based on 
their activation status. Immature DCs are characterized by expression of low 
levels of CD11c, and of co-stimulatory molecules such as MHC II, CD86 and 
CD54, but are very efficient at the phagocytosis of antigen. Following activation, 
immature DCs migrate to the draining lymph nodes, undergo maturation and 
activate naïve T cells leading to generation of antigen-specific, T cell-mediated 
immune responses. Mature DCs are CD11chigh but exhibit a decreased capacity 
to internalize antigens. The activation, maturation and migration of DCs to T cell-
rich areas such as lymph nodes can be triggered by phagocytic uptake of 
antigens or exposure to pathogen-associated molecular patterns (PAMPs) such 
as LPS (Winzler et al., 1997a; Winzler et al., 1997b; Banchereau et al., 2001). 
Migration of DCs to lymph nodes is mediated by chemokine receptors such as 
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CCR7 (Gunn, 2003; MartIn-Fontecha et al., 2003; Randolph et al., 2005).  
Deficiency of CCR7 or its primary ligands CCL19 or CCL21, results in abnormal 
lymph node development and dysfunctional leukocyte trafficking (Forster et al., 
1999; Gunn et al., 1999; Mori et al., 2001; MartIn-Fontecha et al., 2003). 
   DCs exist in a variety of subsets specialized in mediating distinct effector 
functions.  In the murine spleen, two distinct subpopulations of DCs have been 
identified phenotypically by the expression of CD11c: CD11chigh and CD11clow 
cells. CD11clow DCs have been characterized to be immature DCs whereas the 
CD11chigh DCs are considered mature. Recently, two functionally distinct 
CD11chigh DC subsets in the spleen were identified based on their expression of 
CD11chighCD8α+DEC205+ and CD11chighCD8α–33D1+ (Dudziak et al., 2007).  
CD8α+DEC205+ DCs are specialized at cross-presentation of antigens to CD8+ T 
cells and at inducing Foxp3+ regulatory T cells (Dudziak et al., 2007; Yamazaki et 
al., 2008). On the other hand, CD8α-33D1+ DCs are more effective at the uptake 
of exogenous Ags and subsequent activation of CD4+ T cells.  
   DCs are sensitive to TCDD, however, limited information exists on the 
effects of AhR activation in these cells.  Because DCs play a key role in the 
generation of successful T cell-mediated immunity, it is important to define the 
potential effects of persistent environmental pollutants such as TCDD on their 
fate and function. Studies conducted by Vorderstrasse and coworkers provided 
an initial characterization of the effects of TCDD on naïve murine DCs.  In these 
studies, TCDD induced a decrease in CD11c+ DCs and also affected the 
expression of key surface co-stimulatory molecules in an AhR-mediated fashion 
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(Vorderstrasse and Kerkvliet, 2001; Vorderstrasse et al., 2003). In a separate 
study, TCDD was reported to enhance the TNF-α-induced maturation of bone 
marrow-derived dendritic cells (BMDCs) rendering them more sensitive to CD95-
mediated apoptosis (Ruby et al., 2005). However, the effects of TCDD on 
specific murine DC subsets remains to be defined and the mechanisms 
underlying the loss of naïve splenic DCs remain to be elucidated.  In the present 
study, we have characterized the fate of distinct DC subsets in the spleen and 
lymph nodes of TCDD-treated naïve mice. In addition, we have explored 
potential mechanisms responsible for TCDD-induced disruption of DC 
homeostasis in unimmunized mice. 
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MATERIALS AND METHODS: 
Animals.  6-8 week old C57Bl/6 mice were purchased from Jackson Laboratory 
(Bar Harbor, ML) and maintained in accordance with UM IACUC standards. 
Animals were provided rodent chow and tap water ad libitum. Breeding pairs of 
AhR knockout mice (AhR-/-) were obtained from Dr. Paige Lawrence (University 
of Rochester) and subsequently bred and maintained at UM. C57Bl/6gld/gld mice 
(B6Smn.C3-Faslgld) possessing a natural mutation in the Fas Ligand gene, 
originally purchased from Jackson Laboratory (Bar Harbor, ML) were generously 
provided by Dr. Andrij Holian University of Montana). C57Bl/6lpr/lpr mice (B6.MRL-
Faslpr) possessing a natural mutation in the Fas gene were obtained from 
Jackson Laboratory (Bar Harbor, ML). For all experiments, animals were 
euthanized by CO2 overdose followed by cervical dislocation. 
TCDD exposure. TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) was obtained from 
Cambridge Isotope laboratories Inc., (Woburn MA), dissolved in anisole and 
diluted in peanut oil. Control mice received vehicle consisting of comparable 
doses of anisole and peanut oil. For all experiments, mice were gavaged once 
with vehicle or an immunosuppressive dose of TCDD (15 µg/kg) (Kerkvliet et al., 
1996). Animals were sacrificed either on day 5 or day 7 after treatment and 
immune tissues harvested for subsequent analyses. 
Preparation of Splenocytes. Spleens were harvested and processed as 
previously described (Shepherd et al., 2001). Briefly, spleens were processed 
between the frosted ends of slides, erythrocytes were depleted by hypotonic lysis 
and cells were washed and resuspended in cold HBBS, 5% FBS, supplied with 
 
 
 65 
20 mM hepes, 50 µg/ml gentamycin and 1.5mM sodium pyruvate (referred to as 
cHBSS). 
Preparation of Popliteal and brachial lymph nodes (PBLNs). Popliteal and 
Brachial lymph nodes were harvested 5 or 7 days after vehicle or TCDD 
treatment. Lymph node tissue was processed using the end of a 1 ml syringe and 
cell strainer in 5 ml of cHBSS.  The cell suspension was centrifuged at RT at 
1200rpm for 10 minutes. The supernatant was discarded and cells resuspended 
in 1 ml of cHBSS. 
 Flow Cytometry.  Immune cells were stained for FACS analyses as previously 
described (Shepherd et al., 2001). Rat, hamster or mouse IgG block was added 
to aliquots of prepared leukocytes for 10 minutes on ice to prevent non-specific 
binding. Splenocytes were stained for 10 minutes on ice with monoclonal 
antibodies (mAb) from Pharmingen (San Diego, CA): CD11c (HL3), CD11b 
(M1/70), B220 (RA3.6B2), Ly6C (AL-21), CD11a (2D7), MHC II (2G9), CD86 
(GL1) and CD40 (3/23); Miltenyi Biotec (CA): DEC205 (NLDC-145); Biolegend 
(San Diego, CA): CD11c (N418), CCR7 (4B12), CD8 (53-6.7), CD54 (YN1/1.7.4); 
and eBioscience  (San Diego, CA): 33D1.  Similarly, PBLNs were stained for 10 
minutes on ice with mAbs to CD11c (N418), CD11a (2D7), MHC II (2 G9), CD86 
(GL1), CD40 (3/23) and CCR7 (4B12). All mAbs used were titrated for optimal 
concentration and appropriately-labeled, isotype-matched mAbs were used as 
controls. Acquisition of 100,000-300,000 events from freshly prepared cells was 
performed using a FACS Aria flow cytometer (BD biosciences) and analyzed by 
BD FACS Diva software (Version 4.0).  
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For detection of apoptosis, immune cells were stained with Annexin V and 
7AAD as per the manufacturer’s instructions (BD Pharmingen).  After surface 
staining for CD11c, cells were resuspended in 1 X Annexin binding buffer, 
incubated with Annexin-V FITC for 15 minutes at room temperature in the dark, 
followed by addition of 7AAD for 10 minutes and analyzed as described above.  
For sorting CD11chigh and CD11clow splenic DCs, mice were injected i.p. 
once daily for l0 consecutive days with 20µg  human recombinant Flt3L 
(Peprotech Inc., New Jersey) as previously described (Maraskovsky et al., 1997; 
Pulendran et al., 1997). Mice were harvested on day 11, splenocytes were 
prepared, stained with CD11c and purified using anti-PE beads from Miltenyi 
Biotec (CA). Cells were sorted in sterile sorting buffer using FACS Aria flow 
cytometer for CD11chigh (>92% purity) and CD11clow populations (>86% purity).  
Western blotting. Lysates were prepared from FACS-sorted splenic CD11chigh 
and CD11clow DCs. Protein concentrations from cell lysates were determined 
using the BCA assay (Pierce, IL). Protein lysates (17µg per lane) were loaded on 
a 4-12 % SDS PAGE gel  (Invitrogen, CA) and transferred onto PVDF membrane 
(Biorad, CA). Anti-AhR antibody (Biomol, PA) was used to specifically detect 
murine AhRb at a dilution of 1:5000 at 4°C overnight. After washes in TBST 
(Tris-buffered saline Tween-20), horseradish peroxidase conjugated goat 
anti-rabbit IgG (Jackson Immuno research laboratories) was used at a dilution of 
1:1000 for 1 hour at room temperature. The membrane was washed and 
incubated in enhanced chemiluminiscence reagent (ECL: Amersham, New 
Jersey). Membranes were visualized and analyzed using Fuji Film Image Reader 
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(Las 3000, Version 2). Similiarly, the membrane was also probed for β-actin 
using anti-β actin antibody (Abcam, MA) and horseradish peroxidase conjugated 
rabbit anti-mouse IgG (Southern biotech, Alabama) as the secondary antibody.  
Statistical analysis.  Results are presented as the mean ± SEM of 6 mice 
unless otherwise indicated. For all experiments, an unpaired t test was used to 
compare the mean of the vehicle-treated group to the mean of the TCDD-treated 
group. Values of p ≤ 0.05 were considered statistically significant. 
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RESULTS 
DC subpopulations in the peripheral immune tissues. Based on the 
expression of CD11c, the murine marker for DCs, splenocytes and PBLNs differ 
in their DC composition. Two distinct subpopulation of DCs, referred to as 
CD11chigh and CD11clow exist in the mouse spleen (Figure 2-1). In contrast, the 
peripheral lymph nodes contain a uniform CD11c+ population with no discernible 
CD11chigh and CD11clow DCs (Figure 2-1). DCs representing an immature 
phenotype, display low levels of co-stimulatory molecules such as MHC II and 
decreased capacity to activate naïve T cells. On the other hand, mature APCs 
mostly display increased levels of costimulatory molecules and are highly 
efficient at T cell stimulation (Sato and Fujita, 2007). 
Effects of TCDD on naïve splenic DC subpopulations. To assess the potential 
sensitivity of DC subsets to TCDD, AhR protein levels were evaluated in purified 
CD11chigh and CD11clow splenic DCs. As shown in Figure 2-1B, both splenic DC 
subpopulations constitutively express comparable levels of AhR. Consistent with 
previous studies, TCDD exposure caused a decline in the percentage and 
number of CD11chigh DCs recovered from the spleen on day 7 (Figure 2-2A+2B) 
(Vorderstrasse and Kerkvliet, 2001). In the majority of experiments, TCDD had 
no effect on the percentage or number of splenic CD11clow DCs on 7 (Figure 2-
2C+2D).  
Costimulatory molecule expression on naïve splenic DCs from TCDD-
treated mice. Expression of co-stimulatory molecules such as MHC II, CD86, 
CD40 and CD11a reflect the activation and/or maturational status of DCs. 
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Figure 2-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-1. (A) CD11c expression on DCs from peripheral immune tissues.  
Histograms represent two distinct populations of dendritic cells in unimmunized 
mice, CD11chigh and CD11c low cells in the spleen or lymph nodes. (B) AhR 
protein levels in splenic CD11chigh and CD11clow DCs. Lysates were prepared 
from Flt3L-treated C57Bl/6 mice. Spleens were harvested on day 11 and DC 
lysates were prepared from FACS-sorted CD11chigh and CD11clow DCs. Purified, 
non-adherent bone marrow-derived dendritic cells (BMDCs) were used as a 
positive control for the expression of AhR. Whole cell lysates were evaluated by 
Western blotting for AhR and β-actin as described in the Materials and Methods. 
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Figure 2-2. TCDD induces a loss of splenic CD11chigh but not CD11clow DCs.   
C57Bl/6 mice were treated with vehicle or TCDD (15µg/kg). Spleens were 
harvested on day 7, processed and phenotyped by FACS analysis as described 
in Materials and methods. Bar graphs represent the percentage and numbers of 
splenic CD11chigh (A, B) and CD11clow (C, D) DCs as determined by flow 
cytometry.  Data represent means ± SEM from 6 mice per treatment group from 
4 independent experiments. * indicates p ≤ 0.05 for the comparision between 
vehicle- and TCDD-treated mice, respectively. 
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Therefore, several key activation markers were evaluated on both splenic CD11c 
populations. TCDD increased the expression of CD86, CD54 and the frequency 
of CD40 on CD11chigh DCs. The frequency of both MHC II and CD11a on 
CD11chigh DCs was downregulated by TCDD. CD11clow cells from TCDD-treated 
mice displayed a decrease in MHC II and CD11a frequency when compared to 
vehicle-treated controls. Although there was no effect on CD40, expression of 
both CD86 and CD54 on CD11clow DC increased following TCDD exposure 
(Table 2-1). 
 Because distinct DC subsets with unique functions have been recently 
characterized in the mouse spleen, we examined the effects of TCDD on these 
DC subsets.  CD11chigh DCs expressing the phenotypic markers CD8α+DEC205+ 
or CD8α-33D1+ occupy different anatomical positions in the spleen and mediate 
distinct effector functions (Dudziak et al., 2007). TCDD caused a 40 percent 
reduction in the number of splenic CD11chigh CD8α- 33D1+ DCs on day 7 but not 
on day 3 or 5 (Table 2-2 and data not shown). This effect was dependent on the 
expression of the AhR as no loss of CD11chighCD8α-33D1+ DCs occurred in AhR 
knockout mice exposed to TCDD (Table 2-2). In contrast, the number of 
CD11chigh CD8α+ DEC205+ DCs subset was unaffected by TCDD. Consistent 
with the study by Vorderstrasse and coworkers, an upregulation of CD8α+ by 10 
percent was observed on CD11chigh DCs isolated from TCDD-treated mice (data 
not shown). 
Additionally, splenic CD11clow cells can be segregated phenotypically into 
two subsets – plasmacytoid DCs (pDCs), which are CD11clowCD11b-Ly6C+B22 
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TABLE 2-1 
Effects of TCDD on the expression of key accessory molecules on splenic DCsa 
 
 
                                     CD11c high DCs                         CD11c low DCs 
                                      Vehicle            TCDD             Vehicle          TCDD 
Percentage 99 ± 0.2 96 ± 0.6* 80 ± 0.5 75 ± 0.7* 
MHC II 
MFI 5228 ± 231 5411 ± 301 1478 ± 77 1298 ± 105 
Percentage 53 ± 3 56  ± 2 53 ± 1.6 54 ± 1.2 
CD86 
MFI 1769 ± 64 2174 ± 163* 1170 ± 9 1379 ± 79* 
Percentage 58 ± 3 70 ± 4* 36 ± 1.3 33 ± 1.8 
CD40 
MFI 546 ± 21 610 ± 46 870 ± 38 758 ± 54 
Percentage 96 ± 0.2 82 ± 0.5* 92 ± 0.6 86 ± 0.3* 
CD11a 
MFI 3912 ± 287 4505 ± 428 3906 ± 397 4305 ± 173 
Percentage 95 ± 0.2 95 ± 0.3 89 ± 0.5 92 ± 0.6 
CD54 
MFI 4450 ± 302 5848 ± 540* 2518 ± 75 3013 ± 165* 
 
a C57Bl/6 mice were treated with TCDD (15µg/kg) or vehicle.  On day 7, spleens 
were harvested and processed as described in the Materials and Methods. 
Expression of activation markers was determined by gating on the CD11chigh and 
CD11clow DCs. Percent positive expression (%) and mean/median fluorescence 
intensity (MFI) was determined for each activation marker. Data represent the 
mean ± SEM of 5-6 mice/treatment and is representative of 2 independent 
experiments * indicates p ≤ 0.05 for the comparision between vehicle- and 
TCDD-treated mice, respectively. 
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TABLE 2-2 
Effects of TCDD on splenic DC subsetsa 
 
                                                                                                      Vehicle        TCDD 
CD8α+DEC205+DCs (x105) 3.2 ± 0.2 2.7 ± 0.7 
AhR +/+ CD11chigh 
CD8α- 33D1+DCs (x105) 6.5 ± 0.6 3.7 ± 0.9* 
CD8α+DEC205+DCs (x105) 6.1 ± 0.6 6.9 ± 1 
AhR-/- CD11chigh 
CD8α- 33D1+DCs (x105) 5.5 ± 0.7 5.3 ± 0.5 
 
 
a C57Bl/6 mice (AhR+/+) and AhR knockout (AhR-/-) mice were treated with vehicle 
or TCDD and 7 days later splenic DC subsets were prepared and analyzed as 
described in the Materials and Methods. Data represent the mean ± SEM from 
four to five mice/treatment. * indicates p ≤ 0.05 for the comparision between 
vehicle-and TCDD-treated mice, respectively.  
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and Interferon-producing killer DCs (IKDCs), which express CD11clowCD11b-
Ly6C-B220+. In our studies neither percentages nor the numbers of splenic pDCs 
or IKDCs were affected following TCDD exposure of naïve mice (data not 
shown). 
Effects of TCDD on the fate of splenic DCs in naive mice. Because TCDD 
selectively decreased CD11chigh DCs in the spleen, we next investigated potential 
mechanisms responsible for this decline. We hypothesized that TCDD-induced 
decreases in the splenic CD11c high cells may be due to at least two outcomes:  
(a) increased DC death via apoptosis, or (b) increased DC emigration out of the 
spleen. 
Fas-FasL interactions have been implicated in the TCDD-mediated death of 
various immune cells including BMDCs (Rhile et al., 1996; Camacho et al., 2001; 
Camacho et al., 2002; Dearstyne and Kerkvliet, 2002; Ruby et al., 2005). 
Therefore, we examined the potential role of Fas and FasL in the TCDD-induced 
loss of splenic CD11chigh DCs. To evaluate this pathway, unimmunized C57Bl/6 
lpr/lpr or C57Bl6 gld/gld mice were treated with vehicle or TCDD for 7 days.  As 
shown in Figure 2-3, TCDD treatment decreased both the percentage and 
number of splenic CD11chigh DCs when compared to vehicle-treated controls, in 
both the Fas–and FasL-deficient mice, respectively. In a separate experiment, 
apoptosis was directly evaluated in splenic DCs from wild-type C57Bl/6 mice on 
day 5 following TCDD exposure using two well-characterized markers of 
apoptosis, Annexin V and 7AAD. TCDD had no effect on the early or late  
 
 
 
 75 
 
Vehicle TCDD
0.5
1.0
1.5
*
Vehicle TCDD
0
3
6
9
12
15
*
Vehicle TCDD
0.0
0.5
1.0 *
Vehicle TCDD
0
2
4
6
8
10
*
A B
C57Bl/6lpr/lpr
C57Bl/6gld/gld
C D
Figure 2-3
 
 
Figure 2-3. The number and percentage of splenic CD11chigh DCs in lpr and 
gld animals are decreased following TCDD exposure. Non-immunized 
C57Bl/6 lpr/lpr mice (A, B), or C57Bl/6 gld/gld mice (C, D) were treated with vehicle 
or TCDD (15µg/kg) and the numbers of resident DCs in the spleen were 
determined on day 7. Data represent the means ± SEM from 5-6 mice per 
treatment group and are representative of two independent experiments for 
C57Bl/6lpr/lpr and one experiment for C57Bl/6gld/gld mice. * indicates p ≤ 0.05 for the 
comparision between vehicle- and TCDD-treated mice, respectively. 
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apoptotic staining profiles of splenic CD11chigh cells when compared to controls 
(Table 2-3). 
DCs reside in the periphery and upon encounter with antigen, undergo 
maturation. Maturation of DCs is characterized by phenotypic changes including 
the induction of the chemokine receptor CCR7 (Sallusto et al., 1998; Forster et 
al., 1999; Gunn, 2003; Scandella et al., 2004; Randolph et al., 2005; Sanchez-
Sanchez et al., 2006). Expression of this receptor allows DCs to home to T cell-
rich areas in draining lymph nodes (Cyster, 1999; Scandella et al., 2002; 
Scandella et al., 2004). We hypothesized that a decrease in splenic CD11chigh 
DCs could be due to CCR7-mediated migration. To address this hypothesis, the 
expression of CCR7 was evaluated on splenic DCs to explore the possibility that 
increased migration might underlie the TCDD-induced decline of splenic 
CD11chigh cells. CCR7 expression was increased on splenic CD11chigh DCs in 
mice on day 5 following TCDD-treatment (Figure 2-4). CCR7 expression on 
CD11clow DCs was unaffected by TCDD (data not shown).  
DCs in the peripheral lymph nodes are affected by TCDD exposure.  
Because TCDD affects homeostasis of splenic DCs, we next examined if DCs 
that reside in peripheral lymph nodes are also affected by TCDD. We evaluated 
the effects of TCDD exposure on DCs in two sets of peripheral lymph nodes, the 
popliteal and brachial lymph nodes. In contrast to the spleen, the peripheral 
lymph nodes in mice contain a uniform CD11c+ DC population with no discernible 
CD11chigh and CD11clow DCs (Figure 2-1). TCDD did not affect the frequency or  
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TABLE 2-3 
Exposure to TCDD does not induce apoptosisa 
 
                                                           Vehicle                                 TCDD 
% Early apoptosis 5.5 ± 0.3 5.3 ± 0.6 
% Late apoptosis 5.6 ± 0.4 5.0 ± 0.2 
 
 
 a C57Bl/6 mice were treated with TCDD (15µg/kg) or vehicle for 5 days and 
spleens were harvested, processed and stained for expression of  CD11c, 
Annexin V and 7AAD as described in Materials and Methods. Mature DCs were 
identified by gating on the CD11chigh cells from vehicle- and TCDD- treated mice. 
Early apoptosis (Annexin V+/ 7 AAD-) and late apoptosis (Annexin V+/7AAD+) 
was evaluated. Data represent the mean ± SEM from 4-5 mice/ treatment.  
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Figure 2-4 
 
 
Figure 2-4. TCDD increases CCR7 expression on splenic CD11chigh DCs. 
C57Bl/6 mice were treated with vehicle or TCDD. On day 5, spleens were 
harvested and processed for flow cytometric analysis as described in the 
Materials and Methods. Representative histograms depict CCR7 expression 
gated on CD11chigh cells from Vehicle- (A) or TCDD-treated mice (B). Values 
shown are mean ± SEM for 4-5 mice per treatment group and are representative 
of two independent experiments. * indicates p ≤ 0.05 for the comparision 
between vehicle- and TCDD-treated mice, respectively. 
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the number of CD11c+ cells in the popliteal and brachial lymph nodes on day 7 
(Figure 2-5).  As shown in Table 2-4, TCDD exposure enhanced expression of 
MHC II and CD40 but did not affect the expression of CD86 and CD11a or alter 
the percentage of CD11c+ DCs that expressed these costimulatory molecules in 
the peripheral lymph nodes. Interestingly, on day 5 and 7 following treatment, 
CD11c+ DCs in the popliteal and brachial lymph nodes of TCDD-treated mice 
expressed increased levels of CCR7 (Figure 2-6 and data not shown). 
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Figure 2-5 
 
 
 
Vehicle TCDD
0
1
2
3
4
5
Vehicle TCDD
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
 
 
 
 
Figure 2-5.  Effects of TCDD on DCs in the peripheral lymph nodes. The 
percentages and number of CD11c+ DCs in the popliteal and brachial lymph 
nodes were determined from mice treated with TCDD (15µg/kg) or vehicle for 7 
days.  Lymph nodes were harvested and DCs analyzed by flow cytometry as 
previously described in the Materials and Methods. Data represent the mean ± 
SEM from 4-6 mice per treatment group. * indicates p ≤ 0.05 for the comparision 
between vehicle- and TCDD-treated mice, respectively 
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TABLE 2-4 
 
Effects of TCDD on the expression of accessory molecules on DCs from 
peripheral lymph nodesa 
 
                                          CD11c+ DCs 
                                           Vehicle                               TCDD 
MHC Class II MFI 1803 ± 13 2828 ± 79* 
CD86 MFI 3961 ± 271 4611 ± 386 
CD40 MFI 814 ± 32 1074 ± 18* 
CD11a MFI 2846 ± 114 2706 ± 89 
 
 
a C57Bl/6 mice were treated with TCDD or vehicle for 7 days and lymph nodes 
were harvested and processed for flow cytometric analysis. For each activation 
marker, results were generated by gating on the CD11c+ DCs from vehicle- and 
TCDD-treated mice to determine the mean/median fluorescence intensity (MFI). 
Results are representative of two independent experiments and the data 
represent the mean ± SEM from 3 mice/treatment. * indicates p ≤ 0.05 for the 
comparison between vehicle- and TCDD-treated mice, respectively. 
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Figure 2-6 
Figure 2-6. Expression of CCR7 is increased on DCs from lymph nodes 
following TCDD exposure. On day 5 following exposure to vehicle or 15 µg/kg 
TCDD, lymph nodes were harvested and analyzed by flow cytometric analysis as 
previously described. Representative histograms depict CCR7 expression on 
CD11c+ cells in mice treated with vehicle (A) or TCDD (B). Values represent the 
mean ± SEM of 5 mice per treatment group. * indicates p ≤ 0.05 for the 
comparison between vehicle- and TCDD-treated mice for 2 independent 
experiments.  
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DISCUSSION 
DCs play an important role in both the innate and adaptive arms of the 
immune system. They are professional antigen presenting cells, which regulate 
induction of T cell-mediated immunity by providing processed antigen to naïve T 
cells. The effects of TCDD exposure on distinct DC subsets in the spleen and the 
lymph nodes have not been previously examined.  In our experiments we have 
evaluated the effects of TCDD on naïve splenic DCs- both CD11chigh and 
CD11clow cells, in addition to naïve DCs in the peripheral lymph nodes. Both 
splenic DC subpopulations constitutively express AhR and therefore expected to 
be sensitive to TCDD. 
Dendritic cells exist in various differentiation stages referred to as 
immature, mature and activated cells, which can be characterized phenotypically 
by their varying expression of the costimulatory molecules MHC II, CD86 and 
CD40. The seminal publication by Vorderstrasse et al., showed that oral 
administration of TCDD induced a loss of splenic CD11c+ DCs in naïve mice 
(Vorderstrasse and Kerkvliet, 2001). Importantly, this study utilized low-density 
gradient separation in the isolation of DCs. This procedure selects for a distinct 
DC subpopulation from immune tissue and also affects DC activation. However, 
consistent with these findings, TCDD decreased the frequency and number of 
CD11c+ DC. This decline was concomitant with modulation of MHC II, CD11a, 
CD40 and CD86 on the remaining CD11c+ DCs in the spleen. Polarization of T 
cell differentiation into a Th1 or Th2 response can be significantly affected by the 
nature of the DC subset interacting with the T cell. A recent study conducted by 
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Dudziak and colleagues, identified two distinct CD11chigh splenic DC subsets in 
mice based on their expression of select phenotypic markers:  CD8α+ DEC205+ 
DCs and CD8α- 33D1- DCs (Dudziak et al., 2007). These two distinct DC subsets 
differ in anatomical location and possess different effector functions (Vremec et 
al., 1992; Dudziak et al., 2007) The CD8α+DEC205+ DCs found in the splenic 
pulp specialize in cross presentation of exogenous Ags to CD8+ T cells and have 
recently also been implicated in the generation and maintainance of splenic 
Tregs (Yamazaki et al., 2008). Present in the mouse spleen, this splenic DC 
subset specializes in uptake of exogenous Ags and the activation of CD4+ T cells 
via MHC II molecules (Dudziak et al., 2007). Our results demonstrate the 
selective effects of TCDD in mediating a decline in the splenic CD11chigh CD8α-
33D1+ population, which are vital for the activation of CD4+ Th1 helper cells. The 
selective loss of this CD4+ T cell activating splenic DC subset, with the 
concomitant retention of the suppressive Treg-inducing CD8α+DEC205+ splenic 
CD11c population by TCDD may predispose naïve mice to be more susceptible 
to blood borne, extracellular pathogens and account for suppressed CD4 T cell 
reponses following TCDD exposure. However, further studies are necessary to 
specifically evaluate the functional capacity of the splenic DC subsets in 
response to extracellular antigens in TCDD-treated mice. Several investigators 
have linked TCDD-induced immunesuppression with induction of Tregs. AhR 
activation leads to generation of apadtive Tregs (Funatake et al., 2005). 
Additionally, Vogel et al., have demonstrated increase in Treg marker Foxp3 in 
spleen of TCDD-treated mice (Vogel et al., 2008). Our present findings provide 
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suggestive evidence that disruption of DC homeostasis following AhR activation 
may contribute to the generation of Tregs and subsequent immune suppression. 
In contrast to the CD11chigh cells, TCDD did not alter the frequency or the 
numbers of splenic CD11clow DCs. However, alteration of activation markers such 
as MHC class II in CD11clow DCs following exposure to TCDD suggests a 
modulation in the differentiation status of these cells. CD11clow DCs can be 
phenotypically and functionally characterized into at least two distinct 
populations, the IKDCs and pDCs. A tolerogenic function has been assigned to 
the pDC population in mice (Rutella et al., 2006). Tolerogenic DCs can induce 
the generation and maintenance of antigen-specific unresponsiveness in central 
and peripheral immune tissues (Steinman et al., 2003). It is thereby possible that 
the immunosuppressive effects of TCDD on T cell activation may be attributable 
to changes in the number and frequency of tolerogenic DCs. Contrary to our 
expectations, both the frequency and the number of pDCs were unaffected by 
TCDD. Collectively in the spleen, TCDD decreased the immunostimulatory 
subset of DCs but did not affect the tolerogenic DCs, essentially increasing their 
relative frequency after 7 days of exposure. 
In sharp contrast to spleen, TCDD did not affect the number or frequency 
of DCs in the lymph nodes. It did however alter their expression of co-stimulatory 
markers such as MHC Class II and CD40. This modulation is reflective of 
alteration of the steady state differentiation status of DCs in lymph nodes upon 
TCDD exposure and establishes that TCDD, either directly or indirectly, has 
effects in the peripheral lymph nodes. Modulation of DC differentiation may alter 
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their functional abilty to interact with T cells and generate an activating immune 
response. 
Exposure to TCDD has been reported to enhance cellular death in several 
leukocyte populations. Fas (CD95), a member of the TNF family is expressed on 
the surface of DCs as well as other immune cells. Upon binding to Fas ligand 
(CD95L), a series of downstream signaling cascades leads to the activation of 
terminal effector caspases and ultimately apoptosis (Adachi et al., 1993; Nagata 
and Golstein, 1995; Peter and Krammer, 1998; Scaffidi et al., 1998; Lenardo et 
al., 1999; Dearstyne and Kerkvliet, 2002). Moreover, Fas-FasL interactions have 
been implicated in the TCDD–induced loss of various immune cells including T 
cells and DCs. (Rhile et al., 1996; Kamath et al., 1999; Camacho et al., 2001; 
Dearstyne and Kerkvliet, 2002; Camacho et al., 2005; Ruby et al., 2005). We 
used Fas- deficient (lpr/lpr) and FasL-deficient (gld/gld) mice, defective in this 
extrinsic apoptotic pathway, to evaluate the possible involvement of Fas/FasL 
interactions in the decline of naïve splenic CD11chigh DCs by TCDD.  Splenic 
CD11chigh DCs in both the gld and lpr mice declined in a manner similiar to that 
observed in the wild-type mice following TCDD exposure, suggesting that Fas-
mediated apoptosis is not responsible for the loss of splenic CD11chigh DCs in 
naïve mice. Collectively, these studies suggest that the TCDD-induced loss of 
naive splenic CD11chigh DCs is independent of Fas-FasL interactions. 
Additionally, no evidence of TCDD-induced apoptosis was detected in the 
CD11chigh DCs using Annexin V and 7-AAD on day 5 following TCDD exposure 
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of naïve mice. Taken together, our results demonstrate an overall lack of 
apoptosis in splenic CD11chigh DCs following exposure to TCDD. 
Alternatively, the decline in splenic CD11chigh DCs upon TCDD exposure 
could be due to induced emigration. CCR7 is a chemokine receptor that plays a 
prominent role in the migration/trafficking of immune cells including DCs. This 
receptor specifically binds two ligands, CCL21 and CCL19, which are expressed 
constitutively by endothelial cells in the lymphatic vessels and high endothelial 
venules. Immature DCs, which comprise the majority of DCs in an unimmunized 
animal, also express this receptor and migrate to the lymph nodes (Sanchez-
Sanchez et al., 2006). However, in the absence of danger signals, these DCs 
contribute to peripheral tolerance against self-antigens (Scandella et al., 2004; 
Sanchez-Sanchez et al., 2006). Premature induction of migration, in the absence 
of danger signals may alter DC homeostasis in the periphery. Specifically for 
DCs, CCR7 expression is increased following activation.  Interestingly, CCR7 
expression was enhanced on the splenic CD11chigh DCs following TCDD 
exposure, suggesting the possibility that these cells were aberrantly being 
induced to emigrate out of the spleen. Also, CCR7 expression increased on DCs 
that resided in the peripheral lymph nodes in unimmunized mice treated with 
TCDD. The possibility exists that TCDD induces the release of proinflammatory 
cytokines by resident cells in the lymph nodes leading to upregulation of CCL21 
on the lymphatic endothelium. Upregulation of a ligand for CCR7 could then 
induce chemotaxis of splenic DCs into the lymph nodes. However, no alteration 
in the frqeuency or the numbers of lymph node DCs was observed with TCDD. It 
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is possible that increased CCR7 expression on lymph node DCs could induce 
their emigration to the source of CCR7 ligands. The role of TCDD-induced 
increased CCR7 expression on lymph node DCs remains to be identified. 
However, additional experiments are necessary to establish if TCDD-induced 
migration of DCs is dependent on alterations in the expression of CCR7 or its 
ligands. 
A seemingly plausible model emerges considering the progressive 
increase in CD11c expression, along with the modulation in the activation 
markers as DC differentiation proceeds (Figure 2-7). It is possible that TCDD 
selectively affects a subset of splenic CD11chigh DCs increasing the CCR7 
expression on these DCs, ultimately leading to their emigration out of the spleen. 
Because DCs acquire enhanced migratory abilities as they undergo 
differentiation, aberrant migration of splenic DCs may underlie the ability of 
TCDD to disrupt DC homeostasis in lymphoid organs. Alteration of DC 
differentiation and homoestasis by TCDD may generate dysfunctional DCs 
leading to immune suppression. 
In conclusion, we have shown that TCDD affects DCs homeostasis by 
selectively decreasing a distinct subset (CD11chigh CD8α- 33D1+ DCs) in the 
splenic tissue of naïve mice. This loss of mature DCs was not attributed to Fas-
mediated apoptosis. Instead, upregulation of CCR7 on the splenic CD11chigh DCs 
provides suggestive evidence that migration of these DCs may be playing a role 
in TCDD-induced loss of splenic CD11chigh DCs. In addition, our results 
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demonstrate increased activation of DCs in both the spleen and the lymph nodes 
following exposure of naïve mice to TCDD.  
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Figure 2-7. Schematic diagram of the effects of TCDD on splenic CD11chigh 
DCs. 
A) In naïve condition, splenic CD11chigh DC subsets exist in a homeostatic 
balance. The CD11chighCD8-33D1+ DCs, represented in gray reside in the 
marginal zone and interact with CD4+ T cells. The CD11chighCD8+DEC205+ DCs 
residing in the splenic pulp area are specialized at inducing/maintaining Tregs. B) 
Following TCDD exposure the DC homeostasis balance is perturbed. TCDD 
induces the loss of CD11chighCD8-33D1+ DCs and retention of Treg-inducing 
CD11chighCD8+DEC205+ DCs. 
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ABSTRACT 
Aryl hydrocarbon receptor (AhR) activation by its prototypical ligand 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) induces immune suppression. Dendritic cells 
(DCs) are key antigen presenting cells governing T cell activation and 
differentiation. However, the consequences of AhR activation in DCs are not fully 
defined. We hypothesize that AhR activation alters DC differentiation and 
generates dyfunctional DCs. To test this hypothesis, inflammatory BMDCs were 
generated in the presence of vehicle or TCDD. TCDD decreased CD11c 
expression but increased MHC class II, CD86 and CD25 expression on BMDCs. 
The AhR ligands 6-formylindolo[3,2-b]carbazole (FICZ) and 2-(1H-Indol-3-
ylcarbonyl)-4-thiazolecarboxylic acid (ITE) elicited similar effects to TCDD on 
BMDCs. The effects were strictly AhR-dependent but not exclusively DRE-
mediated. TCDD downregulated LPS- and CpG-induced NF-kB p65 levels and 
induced a trend towards upregulation of RelB levels in BMDCs. Induction of 
indoleamine 2,3–dioxygenase (IDO) and TGF-β3 has been implicated in the 
generation of Tregs following AhR activation. AhR activation by TCDD increased 
IDO1, IDO2 and TGF-β3 mRNA levels in BMDCs as compared to vehicle. 
Interestingly, despite the induction of a regulatory phenotype, TCDD-treated 
BMDCs failed to suppress antigen-specific T cell activation. 
Keywords: Aryl hydrocarbon receptor (AhR); dendritic cells (DCs); 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD); NF-kB signaling; Indole amine-2,3-
dioxygenase (IDO) 
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Abbreviations: AhR, Aryl hydrocarbon receptor; Ag, Antigen; BMDCs, Bone 
marrow-derived dendritic cells; DCs, dendritic cells; TCDD, 2,3,7,8-
tetrachlorodibenzo-p-dioxin; TLR, Toll like receptors; FICZ, 6-formylindolo[3,2-
b]carbazole; IDO, Indoleamine-2,3-dioxygenase, ITE, 2-(1H-Indol-3-ylcarbonyl)-
4-thiazolecarboxylic acid.  
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INTRODUCTION 
The Aryl hydrocarbon receptor (AhR) is a ligand-activated transcription 
factor mediating the toxic effects of environmental pollutants such as TCDD. 
Following ligand binding, the AhR translocates into the nucleus, where in 
conjunction with its dimeric partner the Aryl hydrocarbon receptor nuclear 
translocater (ARNT) it binds to dioxin response elements (DREs) in target genes. 
AhR activation has been recognized as the prime mechanism by which 
environmental pollutants such as dioxins exert their adverse effects. The 
prototypical dioxin, 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD), is a high 
affinity, exogenous AhR ligand. Exposure to very low doses of dioxin produces 
immune suppression via activation of the AhR in many animal species, making 
them highly susceptible to infectious diseases and cancer (Kerkvliet, 2002). More 
recently, various tryptophan metabolites such as 6-formylindolo[3,2-b]carbazole 
(FICZ) and 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid (ITE) have been 
described as high-affinity natural AhR ligands (Oberg et al., 2005; Henry et al., 
2006). Few studies have examined the effects of these natural AhR ligands on 
the immune system. Initial studies demonstrated that FICZ, a high affinity AhR 
agonist induced Th17 differentiation and inhibited Treg development by TGF-β 
(Quintana et al., 2008). Contrasting their findings, Kimura et al demonstrated 
Treg induction by TGF-β that was enhanced when the AhR was activated by 
TCDD or FICZ (Kimura et al., 2008). FICZ also increased the expression of 
CD86 on human U937 monocyte-derived DCs (Veldhoen et al., 2008; Vogel et 
al., 2008) Studies conducted by Henry et al., showed that similar to TCDD, ITE 
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alters thymocyte differentiation in vitro (Henry et al., 2006). However, the effects 
of these natural AhR ligands on dendritic cells have not been previously 
described. 
Dendritic cells (DCs) are key immune cells that bridge the gap between 
innate and adaptive immunity. Progressive differentiation of a DC is 
characterized by upregulation of MHC II and costimulatory molecules such as 
B7-2 (CD86) (Sato and Fujita, 2007). In addition to activating T cells, DCs 
constitute part of the first line of defense against invading pathogens and play a 
critical role in the generation of effective innate immunity to pathogenic 
challenge. The prime innate functions executed by DCs are their ability to 
recognize unique pathogen associated molecular patterns (PAMPs) via pattern 
recognition receptors (PRRs) such as toll like receptors (TLRs), ability to uptake 
antigens and secrete cytokines. Additionally, studies have shown the existence 
of distinct DC subsets in vivo (Shortman and Naik, 2007). These include the 
steady-state DCs and inflammatory DCs. Steady-state DCs are mostly lymphoid 
organ resident. The inflammatory DCs, on the other hand, constitute a novel DC 
population that are absent in the steady-state and appear only following an 
inflammatory response. These DCs, characterized by copious production of TNF-
α and expression of inducible NO synthase (iNOS), are derived in vitro using 
GM-CSF/IL4 (Xu et al., 2007).  
 Studies by Vorderstrasse and colleagues established DCs as a sensitive 
target of TCDD, demonstrating a loss of splenic DCs following AhR activation 
(Vorderstrasse and Kerkvliet, 2001). Additional studies have linked functional 
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alterations of DCs to defective T cell responses and immune suppression 
following AhR activation. For instance, studies conducted by Ruby et al., showed 
that TCDD-treatment of BMDCs enhanced TNF-α-induced maturation, and 
augmented CD95-mediated BMDC apoptosis (Ruby et al., 2005). Recently, AhR 
activation by TCDD was also demonstrated to induce down regulation of RelB 
mRNA levels in GM-CSF-derived BMDCs (Lee et al., 2007). DCs play a central 
role in both innate and adaptive immunity, however the effects of AhR activation 
on DCs remain poorly understood. Thus, the aim of this study was to 
characterize the effects of AhR activation on the fate and function of 
inflammatory DCs. We hypothesize that AhR activation alters the differentiation 
of murine inflammatory DCs, an effect that may underlie the generation of TCDD-
induced immune suppression. In this study, we explored the effects of AhR 
activation on DC differentiation, antigen-uptake, TLR responsiveness and 
production of Treg-inducing mediators. Mechanistically, we examined the role of 
DREs in the generation of AhR-induced effects on DCs. The data presented in 
this paper provides new information on the consequences associated with AhR 
activation in DCs.  
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MATERIALS AND METHOD  
Animals:  6-8 week old C57Bl/6 (AhR+/+) mice were purchased from Jackson 
Laboratory (Bar Harbor, ML). Breeding pairs of AhR knockout mice (AhR-/-) were 
kindly provided by Dr. Paige Lawrence (URMC, Rochester, NY). AhRdbd/dbd and 
AhRnls/nls mutant mice were generously provided by Dr. Chris Bradfield and Dr. 
Ed Glover (University of Wisconsin-Madison) and subsequently maintained at 
UM. Animal experiments were approved by the UM IACUC and adhered to the 
current NIH guidelines for animal usage. Animals were provided rodent chow and 
tap water ad libitum. 
Chemicals: TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) in DMSO was obtained 
from Cambridge Isotope laboratories Inc., (Woburn MA). 6-formylindolo[3,2-
b]carbazole (FICZ) and 2-(1H-Indol-3-ylcarbonyl)-4-thiazolecarboxylic acid (ITE) 
were obtained from BIOMOL (Plymouth Meeting, PA) and Tocris (Ellisville, 
Missouri), respectively. DMSO was used as a vehicle for all AhR ligands. Unless 
specified, TCDD was used at a concentration of 10nM. Final concentration of the 
solvent in culture was below 0.1% DMSO and did not induce cytotoxicity. 
Generation of BMDCs: Bone marrow-derived dendritic cells were prepared 
using methods as described by Inaba and coworkers (Inaba et al., 1992). Briefly, 
bone marrow cells were flushed from the femurs of C57Bl/6 or AhR mutant mice 
using complete RPMI (cRPMI) media. Bone marrow cells were centrifuged at low 
speed and red blood cells were removed by gradient centrifugation using 
lympholyte-M (Cedarlane; Hornby, Canada). Bone marrow cells were washed 
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twice and plated at a density of 1x106cells/ml in tissue culture flasks or 6 well 
plates. Cells were cultured in media with 30ng/ml GM-CSF and Vehicle or TCDD 
(10nM) for 3 days at 37° C and 5 % CO2.  On days 3 and 5, non-adherent cells 
were collected washed once and reseeded. Fresh media, GM-CSF (30ng/ml), 
vehicle or TCDD (10nM) was added to the culture flask. Non-adherent cells were 
harvested on day 7 and BMDCs were purified (≥ 85-90%) with CD11c-APC mAb 
and anti-APC beads (Miltenyi Biotec, Auburn, CA) using MACS separation 
columns as per the manufacturer’s instructions. 
Immunophenotypic analysis of BMDCs: BMDCs were stained for FACS 
analysis as previously described (Shepherd et al., 2001). Briefly, rat, hamster or 
mouse IgG block was added to prepared leukocytes for 10 minutes on ice to 
prevent non-specific binding. Cells were stained for 10 minutes on ice cells with 
monoclonal antibodies (mAb) from BDPharmingen (San Diego, CA): CD11c 
(HL3), MHCII (2G9), CD86 (GL1), CD45.2 (104), CD62L (MEL14), CD44 (IM7) 
and Biolegend (San Diego, CA): CD25 (PC61). All mAbs used were optimally- 
titrated and isotype-matched mAbs were used as controls. Acquisition of 40,000-
300,000 events was performed using a FACS Aria flow cytometer. (BD 
biosciences) and analyzed by BD FACS Diva software  (Version 4.0). 
Activation of BMDCs with TLR ligands and cytokine assays: Purified vehicle 
or TCDD-treated BMDCs were cultured in 6 well plates at a density of 1x106 per 
well and stimulated with LPS at 1 µg/ml (Sigma) or CpG at 0.5µM (Invivogen, SA, 
USA) for 24 hrs. IL-6, TNF-α, IL-12p70 and IL-10 levels in the supernatants from 
TLR ligand-stimulated BMDCs were measured by enzyme linked immunosorbent 
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assay (ELISA). Samples were analyzed as per the manufacturer’s instructions 
using cytokine-specific BD ELISA kits (BD Pharmingen)  
NO measurement: NO levels in supernatants from TLR-activated BMDCs were 
assessed using the Griess assay. The assay was conducted as per the 
manufacturer’s instructions (Promega, Madison, USA).  
Antigen uptake:  To measure phagocytic potential, BMDCs were incubated with 
acetylated LDL-FITC (Molecular probes, Oregon, USA) for 1.5 hours, FITC–
ovalbumin (Molecular probes, Oregon, USA) for 12 hours or latex beads-FITC 
(Polysciences, Warrington, PA) for 6 hours. Antigen uptake was subsequently 
assessed by flow cytometry.  
T cell activation: To assess the ability of BMDCs to activate CD4+ T cell in an 
Ag-specific fashion, the OT II adoptive transfer model was employed.  Briefly, 
CD45.2+ BMDCs were generated in the presence of GM-CSF and TCDD (10nM) 
or vehicle. On day 7, BMDCs were purified and loaded with whole OVA. Vehicle- 
or TCDD-treated, antigen-laden BMDCs (1x106/footpad) were transferred into 
host CD45.1 mice that had previously received TCR transgenic OT II T cells 
intravenously (2x106/mouse) one day prior. Lymph nodes were harvested on day 
4 post-immunization and donor DCs and OT II T cells analyzed by flow 
cytometry. Co-expression of CD45.2/CD11c or CD4+/Thy1.1 was used to track 
donor DCs or OT II T cells, respectively. The activation status of donor OT II T 
cells was assessed phenotypically using the markers CD44 and CD62L. 
Quantitative real-time reverse transcription-polymerase chain reaction 
(qRT-PCR): Total RNA was isolated using Trizol reagent and quantified by 
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absorbance at 260nm. Single strand cDNA synthesis was carried using a RT-
PCR kit (SAbiosciences) and prepared as per the manufacturer’s instructions. 
Specific primers for IDO1, IDO2, TGF-β1, TGF-β2, TGF-β3, latent transforming 
growth factor beta binding protein 3 (Ltbp3), Aldehyde dehydrogenase family 1, 
subfamily A2 (Aldh1a2), Thrombospondin 1 (Thbs1), Plasminogen activator 
(Plat) and β-actin were obtained from SABiosciences. Quantitative detection of 
mRNA expression was performed on a Light cycler Instrument (Biorad IQTM 5, 
Multicolor Real Time PCR Detection Systems) using SYBR green 
(SAbiosciences) according to the manufacturer’s instructions. 
NF-kB activity: Purified BMDCs (1.5x106/well) were stimulated with LPS 
(1µg/ml) or CpG (0.5µM/ml) for 30 minutes in 6-well plates. Cells were harvested 
and nuclear protein extracts prepared using the Active Motif nuclear lysis kit 
(Active Motif, Carlsbad, CA). The protein content of the nuclear extract was 
measured using a BCA protein assay kit (Pierce, Rockford, IL). Nuclear protein 
(2.5 µg/ml per well) was then added to the Active Motif TransAM NF (Motif, 
Carlsbad, CA) and assayed according to the manufacturer’s specifications.  
Statistical analysis: Student’s t test was used to compare means of vehicle-
treated groups to TCDD–exposed groups. Data sets with multiple comparisions 
were evaluated by one-way analysis of variance (ANOVA) with Bonferroni’s post 
test. For analysis, values of p ≤ 0.05 were considered significant. 
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RESULTS  
AhR activation alters BMDC growth and differentiation: We first examined 
the effects of TCDD on the growth of BMDCs. Bone marrow cells were induced 
to differentiate into DCs with GM-CSF in the presence of vehicle or TCDD 
(10nM) for 7 days. On day 7 both adherent and non-adherent fractions were 
harvested. TCDD increased the number of non-adherent cells by 50 percent, but 
had no effect on the adherent cells obtained on day 7 when compared to vehicle-
treated controls (Table 3-1). Both vehicle- and TCDD-treated BMDCs were >95% 
viable (data not shown). Non-adherent cells were immunophenotyped using the 
murine DC marker, CD11c and costimulatory/differentiation markers MHC Class 
II, CD86, CD11a, CD54 and CD25. TCDD increased the frequency of CD11c+ 
BMDCs but decreased the relative expression of this lineage marker when 
compared to vehicle-treated controls. Additionally, TCDD increased MHC II, 
CD86 and CD25 expression but decreased CD11a and CD54 expression on 
BMDCs (Figure 3-1). TCDD altered BMDC differentiation at very low 
concentrations. A concentration of 0.01nM TCDD upregulated the expression of 
CD11c, MHC Class IIhigh and CD86high expression on BMDCs when compared to 
vehicle-treated controls (Figure 3-2). In addition to TCDD, many natural (TCDD-
like) ligands bind and activate the AhR. To examine the affects of non-TCDD 
chemicals on BMDC differentiation, cells were treated with two natural AhR 
ligands, FICZ and ITE. Similar to TCDD, FICZ and ITE decreased CD11c 
expression and increased levels of MHC Class II and CD86 on the BMDCs 
(Figure 3-3).  
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Table 3-1: Effects of TCDD on the number of murine bone marrow dendritic 
cells a 
 
 
  Vehicle TCDD 
Non-adherent  16.3 ± 1.2 24.0 ± 4.6* 
Number of cells (x106) Adherent cells  9.3 ± 0.7 7.1 ± 2.9 
 
a BMDCs were grown in presence of vehicle or TCDD. Cells were harvested on 
day 7 and ennumerated as described in the materials and methods section. 
Viability of the cells was ≥ 95% as determined by trypan blue staining Data 
represent the mean ± SEM of 9 independent samples per treatment group. 
*p<0.05 indicates significant differences between vehicle and TCDD-treated 
groups. 
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Figure 3-1 
 Vehicle TCDD 
Percentage 56.7 ± 0.4 60.6 ± 0.3* CD11c MFI 7737 ± 160 5138 ± 54* 
Percentage 38.7 ± 0.8 60.4 ± 0.6* MHC II MFI 690.8 ± 8 1182 ± 24* 
Percentage 15.7 ± 0.3* 27.2 ± 0.3* CD86 MFI 1905 ± 56 2278 ± 29* 
Percentage 81.2 ± 0.7 53.6 ± 0.7* CD11a MFI 3304 ± 53 2147 ± 20* 
Percenatage 81.7 ± 0.4 67.0 ± 0.5* CD54 MFI 797 ± 24 654 ± 7.2* 
Percentage 4.8 ± 0.2 18.6 ± 0.4* CD25 MFI 1775 ± 8 2204 ± 11* 
 
Figure 3-1: TCDD alters the expression of differentiation markers on 
BMDCs: Bone marrow cells were induced to differentiate into immature DCs with 
GM-CSF in the presence of vehicle (represented by dotted line in the histograms) 
or 10 nM TCDD (thick line as indicated in the histograms).  Isotype staining is 
shown in gray lines. Non-adherent cells were harvested on day 7 and stained 
with CD11c, MHC Class II, CD86, CD54, CD11a and CD25 and their expression 
determined on CD11c+ BMDCs by FACS analysis. Data shown represent non-
adherent cells obtained from 4 separate flasks per treatment group and is 
representative of 3 independent experiments. *p<0.05 indicates significant 
differences between vehicle-and TCDD-treated groups. 
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Figure 3-2: Low concentrations of TCDD alter BMDC differentiation: Bone 
marrow cells were generated in the presence of GM-CSF and vehicle or varying 
TCDD concentrations (0.001nM-10nM). Non-adherent cells were harvested on 
day 7 and stained for CD11c, MHC II and CD86. Expression of MHC II and CD86 
was determined on the CD11c+-gated population. Data represent mean ± SEM of 
6 samples at each concentration. *p< 0.05 indicates significant differences 
between the vehicle- and TCDD-treated group. 
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Figure 3-3: Natural AhR agonists alter BMDC differentiation: Bone marrow-
derived dendritic cells were grown in presence of vehicle or the natural AhR 
agonists, FICZ and ITE. Non-adherent cells were harvested on day 7 and stained 
for CD11c, MHC II and CD86. Expression of MHC II and CD86 was determined 
on CD11c+-gated population. *indicates significant differences between treated 
and respective vehicle control groups. Data represent mean ± SEM of 4 samples 
per treatment group for 2 independent experiments. 
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Effects of TCDD on BMDC differentiation are AhR-dependent but are not 
exclusively DRE-mediated: To define the role of the AhR in TCDD-induced 
alterations in the differentiation of BMDCs, we analyzed BMDCs from AhR-/-, 
AhRdbd/dbd and AhRnls/nls mice. TCDD did not affect CD11c, MHC II and CD86 
expression on AhR-/- BMDCs when compared to vehicle-treated controls (Figure 
3-4). AhRnls/nls and AhRdbd/dbd mice express a mutant AhR that binds ligand but 
fails to translocate in the nucleus or bind DREs, respectively. BMDCs from 
AhRdbd/dbd mutant mice displayed decreased CD11c and increased MHC II and 
CD86 expression following TCDD treatment (Figure 3-4). On the other hand, 
BMDCs from AhRnls/nls mice displayed decreased CD11c and CD86, and a slight 
but significant increase in the expression of MHC II following TCDD treatment. 
Effects of TCDD on TLR responsiveness and TLR ligand-induced 
production of inflammatory mediators: To evaluate the effects of TCDD on 
the innate responsiveness of BMDCs, cells were cultured with the TLR ligands, 
LPS (TLR4 agonist) and CpG (TLR9 agonist).  Consistent with our previous 
results, TCDD increased MHC class IIhigh expression on unstimulated BMDCs 
when compared to the unstimulated vehicle controls (Figure 3-5). As expected, 
LPS- and CpG-treatment increased MHC Class IIhigh frequency of BMDCs when 
compared to the unstimulated controls. TCDD significantly increased the LPS-
and CpG-induced frequency of BMDCs expressing high levels of MHC Class IIhigh 
compared to respective vehicle-treated controls. TLR4 and TLR9 mRNA  
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Figure 3-4. The effects of TCDD on BMDCs are AhR-dependent and partially 
DRE-dependent: BMDCs from AhR+/+, AhRdbd/-, AhRdbd/dbd and AhRnls/nls were 
treated with vehicle or TCDD. Non-adherent cells were harvested on day 7 and 
stained for CD11c, MHC II and CD86. Expression of MHC II and CD86 was 
determined on the CD11c gated population and analyzed by Facs aria. Data 
represent mean ± SEM of non-adherent cells obtained from 3-4 flasks per 
treatment goup. *p<0.05 indicates significant differences between respective 
vehicle- and TCDD-treated groups.  
 
 
1000
3000
5000
7000
9000
11000
*
0
250
500
750
1000
1250 *
0
500
1000
1500
2000
2500 *
0
1000
2000
3000
4000
5000
6000
7000
*
*
0
250
500
750
1000
1250
1500
1750 *
*
0
200
400
600
800
1000
1200 *
*
1000
3000
5000
7000
9000
11000
*
*
0
500
1000
1500
2000
2500
3000
3500
*
*
0
500
1000
1500 *
*
AhR-dependency
DRE-dependency
CD11c MHC  II CD86
Figure 3-4
 
 
 113 
0
10
20
30
40
50
*
**
#
#
#
#
Figure 3-5
 
Figure 3-5. Effects of TCDD on LPS- and CpG–induced MHC Class IIhigh 
expression: BMDCs were grown in vehicle or TCDD and non-adherent cells 
were harvested on day 7. BMDCs were purified and treated with LPS or CpG for 
24 hours. Cells were harvested after 24 hours and MHC class II expression was 
assessed. Data represent mean ± SEM of 9 samples per treatment group and is 
representative of 3 independent experiments. *p<0.05 indicates significant 
differences between the respective vehicle- and TCDD-treated groups. #p<0.05 
indicates significant differences between TLR-stimulated and respective 
untreated groups. 
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expression was not affected by TCDD as measured by RT-PCR (data not 
shown). Additionally, AhR activation by TCDD increased both LPS- and CpG-
induced IL-6 and TNF-α production but decreased NO production by BMDCs 
(Table 3-2). TCDD did not affect IL-10 production by the BMDCs when compared 
to the vehicle-treated controls. Although TCDD did not alter the LPS-induced IL-
12p70 production, it decreased the CpG-induced IL-12p70 production by the 
BMDCs when compared to vehicle-treated BMDCs. 
TCDD decreases LPS- and CpG-induced p65 but not RelB activity: NF-kB 
signaling in DCs is activated following TLR stimulation. Additionally, based on the 
potential of ligand-activated AhR to physically interact with NF-kB and alter 
immune function, we evaluated NF-kB signaling in BMDCs (Ruby et al., 2002; 
Vogel et al., 2007a). TCDD decreased p65, but not RelB activity in unstimulated 
BMDCs when compared to unstimulated vehicle controls. LPS- and CpG-
treatment increased p65 but not RelB activity in BMDCs when compared to the 
unstimulated controls. TCDD significantly decreased LPS-and CpG-induced p65 
activity in BMDCs when compared to respective vehicle-treated controls. TCDD 
generated a trend towards upregulation of LPS- and CpG-induced RelB levels in 
BMDCs when compared to the respective vehicle-treated controls (Figure 3-6).  
Antigen uptake by BMDCs is modulated by TCDD: Dendritic cells take up 
antigens by phagocytosis and receptor-mediated endocytosis. To monitor the 
effects of TCDD on antigen uptake, BMDCs were evaluated for uptake of both 
soluble and particulate antigens. As determined by flow cytometry, TCDD  
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Figure 3-6. LPS-and CpG-induced p65 but not Rel B activity is reduced by 
TCDD: Vehicle- or TCDD-treated BMDCs were stimulated with LPS (1 µg/ml) or 
CpG (0.5µM) for 0.5 hours. Cells were harvested and nuclear proteins isolated. 
p65 and RelB activity was measured using the TransAM activity ELISA. * 
indicates significant differences between LPS- or CpG-stimulated groups 
compared to respective vehicle-treated control groups. Data represent mean ± 
SEM of 3 samples per treatment group. 
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Table 3-2: Effects of TCDD on cytokine production by BMDCsa 
 TNF-α (pg/ml) 
 Vehicle TCDD 
Media BD BD 
LPS 4286 ± 407 9565 ± 266* 
CpG 5154 ± 207 8556 ± 399* 
 
 IL-6  (pg/ml) 
 Vehicle TCDD 
Media BD BD 
LPS 21960 ± 2000 33080 ± 3592* 
CpG 22660 ± 1135 30590 ± 3029* 
 
 IL-10 (pg/ml) 
 Vehicle TCDD 
Media BD BD 
LPS 1310 ± 76 1538 ± 282 
CpG 694± 64 719 ± 43 
 
 IL-12p70 (pg/ml) 
 Vehicle TCDD 
Media BD BD 
LPS 268 ± 36 271 ± 34 
CpG 640 ± 28 581 ± 20* 
 
 NO (µM) 
 Vehicle TCDD 
Media 0.4 ± 0.1 0.5 ± 0.1 
LPS 20 ± 2.2 4 ± 0.3* 
CpG 16.2 ± 1.5 3.2 ± 0.2* 
 
 
aBMDCs were stimulated with LPS or CpG as described in Materials and 
Methods. Supernatants were collected and levels of TNF-α, IL-6, IL-10 and IL-
12p70 determined by ELISA. Levels of NO were determined using the Griess 
reagent. Data represent mean ± SEM of 4-9 samples for TNF-α, IL-6, IL-10 and 
NO and is representative of 2 independent experiments.  Data represent mean ± 
SEM of 12-15 samples pooled from 2 separate experiments for IL-12p70. * p ≤ 
0.05 indicates significant differences between LPS- and CpG–stimulated BMDCs 
as compared to respective vehicle-treated controls. BD represents below 
detection.  
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decreased BMDC uptake of the soluble antigens, ovalbumin and acetylated-LDL, 
by 25 and 10 percent, respectively (Figure 3-7). Conversely, TCDD increased the 
uptake of the particulate antigen, latex beads, by 40 percent when compared to 
the vehicle-treated controls. 
 AhR activation upregulates mRNA levels of suppressive T reg-inducing 
mediators. Potent T reg-inducing mediators such as IDO1, IDO2, Thbs1 and 
TGF-β3 have been implicated in the generation of immune suppression following 
AhR activation (Lawrence et al., 2008; Marshall et al., 2008; Vogel et al., 2008). 
In this context, we examined the effects of AhR activation on the generation of 
suppressive mediators in BMDCs. TCDD-treated BMDCs upregulated IDO1, 
IDO2 and TGF-β3 levels by 18-, 24- and 11-fold, respectively (Table 3-3). TCDD 
had no effect on the expression of LTBP, Aldh, Thbs1 or Plat in the BMDCs. 
Following LPS treatment, TCDD-BMDCs displayed increased levels of IDO1, 
IDO2, TGF-β1, TGF-β2 and Thbs1 when compared to vehicle-treated BMDCs. 
AhR-activated BMDCs do not inhibit antigen-specific T cell responses: We 
tested the ability of AhR-activated BMDCs to generate antigen-specific T cell 
activation using the modified OT II adoptive transfer model. Vehicle- or TCDD- 
treated donor BMDCs (CD45.2+) were pulsed in vitro with whole ova to load 
these APCs with antigen. Ova-loaded DCs were then used to activate adoptively 
transferred, ova-specific OT II/Thy1.1 CD4+ T cells that had been adoptively 
transferred into CD45.1 host mice. Peripheral lymph nodes were harvested on 
day 4 following BMDC immunizations. Donor DCs obtained from mice receiving  
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Figure 3-7. TCDD alters antigen uptake by BMDCs: Vehicle- or TCDD-treated 
BMDCs were purified and evaluated for the ability to take up FITC-conjugated 
whole ovalbumin (FITC–Ova), low-density lipoprotein (LDL-FITC) and latex 
beads was assessed. Cells were exposed to FITC-conjugated ovalbumin 
overnight, LDL-fitc for 1.5 hours and FITC-latex beads for 6 hours prior to 
harvesting.  Data represent mean ± SEM of 9-12 samples per treatment group 
for 2 independent experiments. * p≤ 0.05 indicates significant differences 
between vehicle- and TCDD-treated samples. 
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Table 3-3: AhR activation alters expression of suppressive mediatorsa 
 
                                               Unactivated                                   LPS-activated 
 Fold change p value Fold change P value 
IDO1 18* 0.0001 22* ≤0.001 
IDO2 24* ≤0.001 25* ≤0.001 
TGFβ1 0.4 0.1 1.8* 0.02 
TGFβ2 0.9 0.9 2.3* 0.008 
TGFβ3 11* 0.001 0.01 0.4 
Ltbp3 0.2 0.3 1.3* 0.001 
Aldh1a2 0.8 0.6 0.6 0.09 
Thbs1 0.4 0.07 1.9* 0.01 
Plat 1.2 0.4 1.0 0.8 
 
aGene expression in resting and LPS-activated BMDCs was evaluated by real-
time RT-PCR. The results are expressed as TCDD-induced fold change after 
normalization with the housekeeping gene, β-actin. N = 3-4 per treatment group. 
* p≤ 0.05 indicates significant differences between vehicle- and TCDD-treated 
BMDCs. 
 
.  
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Figure 3-8. Ability of TCDD-treated BMDCs to activate antigen-specific T 
cells: CD4+ T cells from OT II Thy1.1 were adoptively transferred into congenic 
CD45.1 host mice on day -1 relative to immunization. On day 0, whole ova-
loaded BMDCs, that were either vehicle- or TCDD-treated were injected into 
adoptively transferred mice. On day 4 post-immunization, popliteal lymph nodes 
were harvested from host mice and analyzed by flow cytometry. Analysis was 
based on the differences in the phenotypic expression of cell surface molecule 
between donor DCs (CD45.2/CD11c) and donor T cells (CD4/Valpha2/Thy1.1) 
from host mice (CD45.1/Thy1.2). Data represent mean ± SEM of 4-5 animals per 
treatment group. * p ≤ 0.05 indicates significant differences between vehicle- and 
TCDD–treated groups. Dashed line represents the status of donor T cells in the 
brachial lymph nodes. 
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TCDD-treated BMDCs, displayed reduced MHC Class II frequency when 
compared to vehicle-treated BMDCs. Ova-specific OT II T cells from the popliteal 
lymph nodes exhibited significant clonal expansion when compared to the OT-II 
T cells from non-draining BLNs (Figure 3-8 + data not shown). Host mice, 
immunized with TCDD-treated BMDCs displayed an increase in the number, but 
not the frequency of OT II T cells. Additionally, no differences were observed in 
the expression of the activation markers CD62L and CD44 on donor T cells from 
mice receiving TCDD-treated BMDCs when compared to donor T cells from mice 
receiving vehicle-treated BMDCs (Figure 3-8). 
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DISCUSSION 
 Dendritic cells are professional antigen presenting cells that play an 
important role in both the innate and adaptive arms of the immune systems. In 
this study, we have characterized the consequences of AhR activation on the 
innate and adaptive functions of BMDCs and examined the role of DRE-mediated 
events in the generation of these effects. We demonstrate that AhR activation 
alters BMDC differentiation and induces a regulatory phenotype, but surprisingly 
without altering the ability of the DCs to initiate Ag-specific activation of naïve, 
CD4+ T cells. 
Dendritic cells exist in multiple, functionally distinct stages of 
differentiation. Several investigators have linked TCDD-induced modulation of 
DC differentiation to the generation of defective T cell responses (Vorderstrasse 
and Kerkvliet, 2001; Lee et al., 2007). In our study, TCDD decreased expression 
of CD11c but increased MHC II and CD86 levels on BMDCs. Engagement of B7 
(CD86) molecules on a DC with CD28 or CTLA4 on the surface of the T cell can 
activate or impair T cell responses, respectively (Krummel and Allison, 1995; 
Lenschow et al., 1996). Successful T cell activation involves not only interactions 
between the TCR and Ag-associated MHC II, but also costimulatory interactions 
such as CD28 and CD86. In this context, studies have linked TCDD-induced 
increases in CD86 expression on DCs with increased T cell activation in an MLR 
response (Lee et al., 2007). However, AhR activation has also been shown to 
induce CTLA4 expression on T cells which can bind to CD86 on a DC with high 
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affinity and impair T cell responses (Funatake et al., 2005). Thus, in the context 
of AhR activation, ligation of CD86 on DCs with CTLA4 on T cells could 
alternatively contribute towards the generation of immune suppression. 
Furthermore, consistent with previous studies documenting TCDD-induced 
modulation of the adhesion molecules CD11a and CD54, TCDD decreased the 
expression of both these molecules on BMDCs (Shepherd et al., 2001; 
Vorderstrasse and Kerkvliet, 2001). The decreased expression of adhesion 
molecules on DCs could contribute to defective T cell activation and subsequent 
immune suppression.  TCDD-induced immune suppression has also been linked 
to increased CD25 expression on T cells (Funatake et al., 2005). More recently, 
CD25 was identified as a phenotypic marker for regulatory DCs (DCregs) 
(Driesen et al., 2008) (von Bergwelt-Baildon et al., 2006). TCDD increased CD25 
expression on BMDCs, suggesting the induction of a regulatory phenotype in the 
BMDCs. Taken together, TCDD-induced alteration of molecules involved in Ag-
presentation, costimulation and adhesion could result in defective T cell 
activation contributing to immune suppression. Recently, ligand-specific 
activation of the AhR has been shown to generate Tregs or Th17 cells (Quintana 
et al., 2008). However, the effects of ligand-specific activation in inflammatory 
DCs have not been previously described. Interestingly, the AhR ligands, FICZ 
and ITE generated phenotypical alterations in BMDCs similar to TCDD, 
demonstrating a lack of differential responsiveness of DCs to an array of AhR 
ligands. 
While the AhR is essential for TCDD-induced immunotoxicity, no 
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information exists regarding the role of DREs in TCDD-induced alterations of 
DCs. We investigated the role of the AhR and DREs in TCDD-induced alteration 
in DC differentiation using BMDCs from AhR null, AhRnls/nls and AhRdbd/dbd mice. 
While the AhR null mice, lacking functional AhR receptor, enabled us to 
determine the role of the AhR in the generation of TCDD-induced alterations in 
DCs, involvement of DRE-mediated events was assessed using the AhRnls/nls and 
AhRdbd/dbd mice expressing a mutant AhR that binds ligand but fails to translocate 
into the nucleus or bind DREs, respectively.  Our results show that the effects of 
AhR activation in BMDCs are strictly AhR-dependent but not exclusively DRE-
mediated. TCDD-treated BMDCs from AhRdbd/dbd mice displayed increased MHC 
II and CD86 expression when compared to vehicle-treated AhRdbd/dbd BMDCs. 
However, TCDD-induced increases in MHC II and CD86 expression in AhR dbd/dbd 
BMDCs did not reach similar levels to those observed in TCDD-treated BMDCs 
from AhRdbd/- control mice. This suggested that a non-DRE mediated mechanism 
was contributing to the TCDD-induced differentiation of the DCs. Of the several 
non-DRE mediated mechanisms implicated in TCDD immunotoxicity, interactions 
of the activated AhR with NF-kB signaling components can induce defects in 
DCs following TCDD exposure (Ruby et al., 2002; Vogel and Matsumura, 2008). 
Thus, one possible explanation for the partial effects of TCDD on BMDC 
differentiation as observed in DCs from AhRdbd/dbd and AhRnls/nls mice could be 
due to altered NF-kB signaling.  
A primary function of DCs is the recognition of PAMPs via PRRs such as 
TLRs. Based on the observed TCDD-induced modulation of DC differentiation, 
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we assessed whether TCDD-exposed BMDCs were responsive to PAMPs via 
TLR activation. TCDD increased BMDC responsiveness to TLR stimulation via 
TLR4 and TLR9 without affecting the basal mRNA levels of these receptors. 
Following activation DCs secrete cytokines that orchestrate developing immune 
responses. In our study, TCDD increased LPS- and CpG-induced IL-6 and TNF-
α production by BMDCs but decreased their production of nitric oxide. Multiple 
possibilities could account for these observed effects. NF-kB independent 
transcription factor, LPS-Induced TNF-α Factor (LITAF), is a transcription factor 
that has been implicated in the LPS-induced expression of TNF-α and other 
inflammatory cytokines (Sun et al., 2004; Tang et al., 2005). LITAF contains 7 
DRE sequences and upregulation of LITAF in DCs could underlie our observed 
TCDD-induced increases in LPS-induced proinflammatory cytokine secretion 
(Sun et al., 2004). Recent studies have, however, documented the ability of 
activated AhR to negatively regulate inflammatory responses in human 
monocyte-derived DCs and murine macrophages (Lawrence et al., 2008; Kimura 
et al., 2009). Discrepancies in these results could be attributed to differences in 
the AhR agonists used in the respective studies (VAGF347 versus TCDD) or in 
the cells that were examined (human monocyte DCs versus murine DCs or 
macrophages). In addition, activation of inflammatory DCs by LPS or CpG 
usually induces upregulation of nitric oxide synthase (NOS) and subsequently 
increased NO production. AhR activation by TCDD has been shown to increase 
pulmonary inducible NO synthase (iNOS) levels contributing to enhanced IFN-γ 
production in the lungs (Neff-LaFord et al., 2007). Contrary to these reports, in 
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our study TCDD decreased NO production by both unstimulated and TLR-
activated BMDCs. Additonal investigation is warranted to further understand the 
effect of TCDD on NO production by BMDCs. 
 A previous study examining the effects of TCDD on BMDCs reported 
decreased mRNA levels of IL-10 but not IL-12 following LPS-stimulation (Lee et 
al., 2007). Contrary to this study, our data indicates that TCDD does not alter the 
production of IL-10 and decreases CpG-induced IL-12 production by BMDCs. 
Different DC preparations (unpurified versus purified DCs) used in these two 
studies could account for the observed differences. Under in vivo conditions, 
inflammatory DCs function to limit infection by their secretion of inflammatory 
cytokines. Induction of inflammation is a hallmark feature of TCDD-induced 
immunotoxicity and our results suggest a role for DCs in TCDD-induced 
inflammatory responses. However, how TCDD-induced alterations of 
inflammatory DCs impacts the development of acute inflammation remains to be 
determined.  
NF-kB is a major signaling pathway involved in the differentiation of DCs 
and their responsiveness to TLR stimulation. Furthermore, several studies have 
linked physical interactions of activated AhR with NF-kB p65 and RelB, in the 
generation of TCDD-induced cellular dysfunction and immune suppression (Ruby 
et al., 2002; Camacho et al., 2005; Vogel et al., 2007a; Vogel et al., 2007b; Vogel 
and Matsumura, 2008). Because TCDD alters the differentiation of DCs and their 
responsiveness to TLRs, we investigated the effects of AhR activation on NF-kB 
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signaling in inflammatory BMDCs. TCDD suppressed basal p65 activity in 
unstimulated BMDCs as well as BMDCs activated by LPS and CpG. 
Furthermore, a trend towards increased RelB activity was also observed in 
TCDD-treated BMDCs. Binding of RelB/AhR to specific response elements 
(RelB/AhRE) in certain target genes has been linked to the regulation of 
cytokines and chemokines such as IL-8 and BLC following TCDD exposure 
(Vogel et al., 2005; Vogel et al., 2007b; Vogel and Matsumura, 2008). It would be 
of interest to determine if the enhanced production of IL-6 and TNF-α by TCDD-
treated BMDCs is also regulated by increased interactions between activated 
AhR and RelB. Overall, our data suggest that TCDD-induced modulation of DC 
differentiation and their responsiveness to TLR stimulation may be mediated via 
altered NF-kB signaling.  
Dendritic cells capture antigens via distinct mechanisms. While soluble 
antigen uptake primarily involves macropinocytic or receptor-mediated endocytic 
events, particulate antigens are internalized primarily via phagocytosis 
(Banchereau et al., 2000). TCDD decreased the uptake of the soluble antigens 
ovalbumin and LDL but increased phagocytosis of latex beads by inflammatory 
DCs. These results suggest that TCDD differentially impacts mechanisms of 
antigen uptake. Studies have shown macrophage mannose receptor and 
scavenger receptor A to mediate the endocytosis of ova and acetylated LDL, 
respectively (Pearson et al., 1993; Becker et al., 2006; Burgdorf et al., 2007). 
Therefore, based on our results, we hypothesize that decreased expression of 
these receptors in BMDCs following exposure to TCDD leads to decreased 
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uptake of soluble antigens. Conversely, TCDD increased the uptake of latex 
beads by BMDCs. So far, only one study has described effects of TCDD on the 
uptake of latex beads. In this in vivo study, uptake of latex beads by splenic DCs 
was unaffected following TCDD exposure (Vorderstrasse et al., 2003). The 
observed discrepancy in our results could be attributed to distinct antigen uptake 
mechanisms in the two functionally distinct DC populations (steady-state versus 
inflammatory), which could be differentially affected by TCDD. 
 Because our data demonstrated that TCDD altered antigen uptake, we 
assessed the effects of TCDD on the T cell stimulatory capacity of inflammatory 
BMDCs. Surprisingly, TCDD-treated BMDCs generated normal antigen-specific T 
cell responses in vivo. These results were unexpected, as TCDD not only 
induced a regulatory phenotype in BMDCs, but also increased their expression of 
several regulatory mediators including IDO1, IDO2 and TGF-β3. Several 
possibilities could account for the lack of T cell suppression by TCDD-treated 
BMDCs. Though our results demonstrated that TCDD alters antigen uptake of 
ovalbumin by BMDCs, it is possible that the observed decreases in antigen 
uptake do not reach a physiological threshold below which T cell activation is 
affected. Additionally, TCDD may increase the expression, but not the function or 
activity of the suppressive mediators IDO1, IDO2 and TGF-β3. In this case, we 
would not expect TCDD-treated BMDCs to contribute to the suppression of T cell 
activation. Recent studies have linked AhR activation in DCs with suppression of 
T cell responses (Hauben et al., 2008). In these studies, AhR-activated DCs 
suppressed T cell responses only following LPS activation. Immature BMDCs did 
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not alter T cell responses. Thus, we also evaluated the expression of the 
suppressive mediators in BMDCs following LPS maturation. TCDD-treated 
BMDCs stimulated with LPS displayed increased expression of IDO1, IDO2, 
TGF-β1, TGF-β2 and Thbs1.  However, future experiments are needed to 
determine whether TCDD-treated BMDCs stimulated with LPS can affect 
antigen-specific T cell responses.  
Collectively, we show that AhR activation alters inflammatory DC 
differentiation, generating DCs that are hyperresponsive to TLR stimulation and 
exhibit a regulatory phenotype in vitro. Surprisingly, these BMDCs fail to alter 
antigen-specific T cell activation. However, further studies are needed to 
examine the potential for AhR-activated DCs to contribute to the generation of 
regulatory T cells and the suppression of T cell-mediated immune responses.   
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ABSTRACT 
Although Aryl hydrocarbon receptor (AhR) activation by its prototypical 
ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces regulatory T cell 
(Tregs), molecular mechanisms underlying immunosuppression are not well 
understood. Dendritic cells (DCs) are key antigen presenting cells governing T 
cell activation and differentiation. DCs are sensitive to TCDD and AhR activation 
induces a regulatory phenotype in DCs. We hypothesize that AhR-activated 
dendritic cells (DCs) induce the generation of adaptive Tregs ultimately 
contributing to immune suppression. To test this hypothesis, purified bone 
marrow-derived DCs (BMDCs), generated in the presence of vehicle or TCDD 
were assessed for induction of adaptive Tregs in vitro. Additionally, suppression 
of T cell activation in vivo by LPS-stimulated, vehicle- and TCDD-treated BMDCs 
was assessed. TCDD-treated BMDCs did not induce the generation of adaptive 
T regs in vitro or suppress T cell activation in vivo. These results suggest that 
AhR-activated regulatory DCs do not induce the generation of adaptive Tregs 
and that AhR-induced Treg development may be a direct effect of AhR activation 
on T cells. Alternatively, AhR-activated DCs may contribute to the expansion of 
natural Tregs, a possibility that remains to be tested.  
Keywords: Aryl hydrocarbon receptor (AhR); dendritic cells (DCs); 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD); Indole amine-2,3-dioxygenase (IDO) ; FICZ, 
6-formylindolo[3,2-b]carbazole. 
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Abbreviations: AhR, Aryl hydrocarbon receptor; Ag, Antigen; BMDCs, Bone 
marrow-derived dendritic cells; DCs, dendritic cells; TCDD, 2,3,7,8-
tetrachlorodibenzo-p-dioxin TCDD; IDO, Indoleamine-2,3-dioxygenase. 
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INTRODUCTION 
TCDD is an environmental pollutant that induces profound 
immunosuppression via activation of the Aryl hydrocarbon receptor (AhR)(Ema et 
al., 1994b; Okey et al., 1994). Following ligand binding, the AhR translocates into 
the nucleus, where in conjunction with its dimeric partner the Aryl hydrocarbon 
receptor nuclear translocater (ARNT) it binds to the dioxin response elements 
(DREs) in target genes.  Several studies have documented TCDD exposure to 
decrease CD4+ T cell function and induce the generation of regulatory T cells 
(Tregs), which function to maintain tolerance (Kerkvliet et al., 2002; Quintana et 
al., 2008). Two distinct types of regulatory T cells have been described: natural 
Tregs that arise in the thymus, and inducible/adaptive Tregs, that form from 
CD4+CD25-Foxp3- precursors in the periphery (Shevach, 2006; Sakaguchi et al., 
2008; Yamazaki and Steinman, 2009).  
Several investigators have described the induction of Tregs following 
TCDD exposure (Funatake et al., 2005; Marshall et al., 2008; Quintana et al., 
2008). Additionally, the increase in Tregs following AhR activation has been 
associated with an increased production of Treg mediators including TGF-β3 and 
indoleamine-2, 3-dioxygenases (IDO) (Marshall et al., 2008; Vogel et al., 2008). 
Despite these reports, little is known about the mechanisms underlying 
generation of Tregs following TCDD exposure.  
Dendritic cells (DCs) are central antigen presenting cells that express the 
AhR constitutively. We have previously demonstrated that TCDD induces a 
regulatory phenotype in BMDCs that is characterized by an increased expression 
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of IDO1, IDO2 and TGF-β3. Thus, the induction of regulatory DCs following AhR 
activation may underlie generation of Tregs and subsequent immune 
suppression. We hypothesize that AhR-activated DCs promote the generation of 
adaptive Tregs. In this study, we evaluated the role of DREs in the TCDD-
induced expression of suppressive regulatory mediators in BMDCs and 
examined the ability of TCDD-exposed APCs to induce Tregs. 
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MATERIALS AND METHODS  
Animals:  6-8 week old C57Bl/6 (AhR+/+) mice were purchased from Jackson 
Laboratory (Bar Harbor, ML). Breeding pairs of AhR knockout mice (AhR-/-) were 
kindly provided by Dr. Paige Lawrence (URMC, Rochester, NY). AhRnls/nls and 
AhRdbd/dbd mice were initially acquired from Dr. Chris Bradfield and Dr. Ed Glover 
(University of Wisconsin-Madison) and subsequently bred and maintained at UM. 
AhRnls/nls and AhRdbd/dbd mice bear a mutant AhR that binds the ligand, but is 
defective in nuclear translocation and binding the DREs, respectively. Animal 
experiments were approved by the UM IACUC and adhered to the current NIH 
guidelines for animal usage. Animals were provided rodent chow and tap water 
ad libitum. 
Chemicals: TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin) in DMSO was obtained 
from Cambridge Isotope laboratories Inc., (Woburn MA). 6-formylindolo[3,2-
b]carbazole (FICZ) was obtained from BIOMOL. DMSO was used as a vehicle 
for all AhR ligands. TCDD and FICZ were used at a concentration of 10nM. Final 
concentration of the vehicle in culture was below 0.1% DMSO and did not induce 
cytotoxicity. rIL-2  was obtained from R and D systems (Minneapolis, MN) and 
TGF-β1 was obtained from ebiosciences (San  Diego, CA). 
Generation of BMDCs: Bone marrow-derived dendritic cells were prepared 
using methods from Inaba et al. (1992). Briefly, the bone marrow cells were 
flushed using complete RPMI (cRPMI) media from the bone shafts of C57Bl/6 or 
AhR mutant mice. Bone marrow cells were centrifuged at low speed and red 
blood cells were removed by gradient centrifugation using lympholyte-M 
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(Cedarlane, Hornby, Canada). Bone marrow cells were washed twice and plated 
at a density of 1x106cells/ml in tissue culture flasks. Cells were cultured in media 
with GM-CSF (30ng/ml) and Vehicle or TCDD (10nM) for 7 days at 37° C and 5 
% CO2.  On days 3 and 5, non-adherent cells were collected washed once and 
reseeded back into culture flask. Fresh media, GM-CSF (30ng/ml), vehicle or 
TCDD (10nM) was added to the culture flask and ultimately non-adherent cells 
harvested on day 7. BMDCs were purified (≥85-90%) using CD11c-APC antibody 
and anti-APC beads (Miltenyi Biotec, Auburn, CA) or CD11c beads (Miltenyi 
Biotec, Auburn, CA). Following purification, BMDCs were loaded with ova-
peptide (50µg/ml cPRMI) and harvested after 2 hours. For some experiments 
BMDCs were simultaneously treated with LPS (1µg/ml) and ova-peptide 
(50µg/ml cPRMI) and harvested after 12 hours.  
T cell purification: Splenocytes were isolated from OT II mice and prepared as 
previously described (Shepherd et al., 2001). CD4+ cells were isolated using the 
CD4 T cell isolation kit as per the manufacturer’s instructions (Miltenyi, CA). Cell 
purity as determined by flow cytometry was ≥ 90%. Purified CD4+ cells were 
labeled with anti-CD25 PE and MACS anti-PE beads and positively selected 
using LS columns (MACS separation columns). The purity of CD4+CD25+ and 
CD4+CD25- cells obtained was 75% and 85%, respectively.  
Immunophenotypic analysis of BMDCs and T cells: Harvested immune cells 
were stained for FACS analysis as previously described (Shepherd et al., 2001). 
Briefly, rat, hamster or mouse IgG block was added to prepared cells for 10 
minutes on ice to prevent non-specific binding. Cells were stained for 10 minutes 
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on ice cells with monoclonal antibodies (mAb) from BDPharmingen (San Diego, 
CA): CD11c (HL3), MHCII (2G9), CD86 (GL1), CD62L (MEL14), CD44 (IM7) and 
Biolegend (San Diego, CA): CD25 (PC61). All mAbs used were optimally titrated 
and appropriately-labeled, isotype-matched mAbs were used as controls. 
Acquisition of 40,000-50,000 events was performed using a Facs Aria flow 
cytometer. (BD biosciences) and analyzed by BD FACS Diva software  (Version 
4.0). 
Quantitative real-time reverse transcription-polymerase chain reaction 
(qRT-PCR): Total RNA was isolated using Trizol reagent and quantified by 
absorbance at 260nm. Single strand cDNA synthesis was performed using a RT-
PCR kit (SAbiosciences) and prepared as per the manufacturer’s instructions. 
Specific primers for IDO1, IDO2, TGFβ-1, TGF-β2, TGF-β3, latent transforming 
growth factor beta binding protein 3 (Ltbp3), Aldehyde dehydrogenase family 1, 
subfamily A2 (Aldh1a2), Thrombospondin 1 (Thbs1), and β-actin were obtained 
from SABiosciences. Quantitative detection of mRNA expression was performed 
on a Light cycler Instrument (Biorad IQTM 5, Multicolor Real Time PCR Detection 
Systems) using SYBR green (SAbiosciences) according to the manufacturer’s 
instructions. 
In Vitro Suppression Assay: Purified CD4+CD25+ cells were suspended at a 
final concentration of 1x106 cells/ml in complete RPMI (cRPMI) media and 
cultured in 6 well plates coated with plate bound anti-CD3 (2µg/ml) and 
supplemented with rIL-2 (250U/ml) and TGF-β1 (2ng/ml). CD4+CD25- cells were 
co-cultured with DCs in a suppression assay as described below. Purified, 
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vehicle- or TCDD-treated BMDCs (1x106/ml) were loaded with ova-peptide 
(OVA323-339) for 2 hrs in 6 well plates. Ova-peptide loaded DCs were 
subsequently co-cultured with purified, CD4+CD25- OT II T cells at a DC to T cell 
ratio of 1:4, at a final concentration of 1 x106/ml in 6 well plates. After 4 days in 
culture, cells were harvested and stained for CD4, CD25 and Foxp3.   
T cell activation: To assess the ability of LPS-activated BMDCs to activate 
CD4+ T cell in an antigen-specific fashion, the OT II adoptive transfer model was 
employed.  Briefly, CD45.2+ inflammatory BMDCs were generated in the 
presence of vehicle or TCDD (10nM), purified and subsequently treated with LPS 
(1µg/ml) and ova-peptide (50µg/ml) for 12 hrs. LPS-activated, ova-peptide 
loaded BMDCs were injected (1x106/footpad) into host CD45.1+ congenic mice 
that had previously received one day prior OT II T cells (2x106/mouse) 
intravenously. Popliteal Lymph nodes were harvested on day 5 post-
immunization, processed and donor DCs and OT II T cells identified by flow 
cytometry. The expression of CD45.2+/CD11c+ or CD4+/Thy1.1+ cells was 
employed to track donor DCs or OT II T cells, respectively. The activation status 
of antigen-specific donor OT II T cells was assessed immunophenotypically using 
the markers CD44 and CD62L. 
Statistical analysis: Student’s t test was used to compare the means of vehicle-
treated groups to TCDD–exposed groups. For analysis, values of p ≤ 0.05 were 
considered significant.  
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RESULTS 
TCDD-induced expression of IDO1 and IDO2 and TGFβ-3 in BMDCs is AhR-
dependent. We have previously shown that AhR activation by TCDD increases 
the expression of IDO1, IDO2 and TGFβ-3 in inflammatory BMDCs. To 
determine the role of the AhR in the induction of these mediators, we assessed 
their expression in vehicle- or TCDD-treated BMDCs from AhR null and wildtype 
mice. As shown in table 4-1, TCDD increased the expression of IDO1, IDO2 and 
TGFβ3 in AhR wild type mice. On, the other hand, TCDD did not alter gene 
expression in AhR KO BMDCs, suggesting that the induction of these mediators 
following TCDD exposure was AhR-dependent (Table 4-1). 
TCDD-induced expression of IDO1 and IDO2 but not TGF-β3 in BMDCs is 
DRE-dependent: To determine the role of the DRE-mediated events in the 
induction of these mediators, we assessed their expression in BMDCs from 
AhRdbd/dbd and AhRnls/nls mice.  TCDD-treated BMDCs from AhRdbd/dbd increased 
TGFβ-2 and TGFβ-3 mRNA expression by 1.6- and 2.9- fold, respectively (Table 
4-2A). Additionally, TCDD increased the expression of TGF-β2, TGF-β3, Aldh1a 
and Thbs in BMDCs from AhRnls/nls mice by 2.3-, 6.2-, 2.6- and 1.6-fold, 
respectively (Table 4-2B). 
FICZ, a natural AhR ligand, increases expression of Treg-inducing 
mediators. More recently, tryptophan metabolites such as 6-formylindolo[3,2-
b]carbazole (FICZ) have been described as high-affinity natural AhR ligands 
(Oberg et al., 2005; Henry et al., 2006). Our previous studies have demonstrated 
that FICZ generates phenotypical alterations in inflammatory BMDCs, similar to 
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Table 4-1: The AhR is required for TCDD-induced changes in the 
expression of regulatory mediatorsa 
 
 
 
aGene expression was evaluated in AhR  wild-type and AhR null  BMDCs by qRT-
PCR. The results are expressed as TCDD-induced fold change when compared 
to the vehicle-treated controls after normalization with the housekeeping gene, β 
actin. The experiment was conducted with N = 3 per treatment group. *p ≤ 0.05 
was considered significant for all analysis conducted between vehicle-treated  
and TCDD-treated BMDCs. 
 
 
 
 
 
 
TCDD-induced fold 
change in AhR wildtype 
BMDCs 
p value 
TCDD-induced fold 
change in AhR-/- 
BMDCs 
p value 
IDO1 18* 0.0001 0.6 0.4 
IDO2 24* ≤0.001 1.3 0.2 
TGFβ1 0.4 0.1 0.9 0.8 
TGFβ2 0.9 0.9 0.9 0.8 
TGFβ3 11* 0.001 0.5 0.1 
Ltbp3 0.2 0.3 1.0 0.9 
Aldh1a2 0.8 0.6 1.0 0.6 
Thbs1 0.4 0.07 1.1 0.1 
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Table 4-2: Role of DRE-mediated events in the TCDD-induced gene 
expression of regulatory mediators in BMDCs 
 
A.  
 
 TCDD-induced 
fold change in 
AhRdbd/- BMDCs 
p value TCDD-induced 
fold change in 
AhRdbd/dbd BMDCs 
p value 
IDO 1 4.5* 0.003 -1.5* 0.03 
IDO 2 7.6* 0.0004 0.8 0.6 
TGFβ1 0.8 0.3 0.8 0.2 
TGFβ2 1.7 0.2 1.6* 0.04 
TGFβ3 15* ≤0.001  2.9* 0.008 
Ltbp3 -1.8* 0.02  -2.1* 0.005 
Aldh1a 1.4 0.2 1.5 0.07 
Thbs1 0.8 0.5 0.1 0.1 
 
B.  
 
 TCDD-induced 
fold change in 
AhRdbd/- BMDCs 
p value TCDD-induced 
fold change in 
AhRnls/nls BMDCs 
p value 
IDO 1 8.5* 0.005 2.5 0.1 
IDO 2 1.9* 0.04 1.2 0.4 
TGFβ1 0.8 0.2 0.8 0.2 
TGFβ2 1.7 0.2 2.3* 0.004 
TGFβ3 8.8* 0.009 6.2* 0.001 
Ltbp3 0.7 0.14 0.9 0.7 
Aldh1a 1.5* 0.004 2.6* 0.001 
Thbs1 1.2 0.33 1.6* 0.01 
 
a Gene expression was evaluated from A) AhRdbd/- and AhRdbd/dbd B) AhRdbd/-and 
AhRnls/nls BMDCs by qRT-PCR. The results are expressed as TCDD-induced fold 
change after normalization with the housekeeping gene, β actin. The experiment 
was conducted with N = 3 per treatment group. *p ≤ 0.05 was considered 
significant for all analysis conducted between vehicle-treated  and TCDD-treated 
BMDCs. 
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TCDD. These results suggest that unlike T cells AhR activation in DCs by 
exogenous or natural AhR ligands is not ligand-specific. To further assess the 
effects AhR activation by a natural ligand, we examined the induction of 
suppressive mediators in BMDCs following FICZ treatment. As shown in table 4-
3, BMDCs displayed an increase in expression of IDO1, IDO2, TGF-β2, TGF-β3 
and Aldh1a following exposure to FICZ when compared to vehicle-treated cells 
(Table 4-3). 
Effects of TCDD-treated BMDCs on the generation of CD4+CD25+ Foxp3+T 
cells in vitro: Regulatory T cells can be segregated into two distinct lineages 
referred to as natural T regs and adaptive Tregs. Several studies have shown 
have linked TCDD-induced immune suppression with the induction of Tregs. 
TCDD induced not only a regulatory phenotype in BMDCs, but also increased 
their expression of several suppressive mediators. We therefore, assessed the 
ability of TCDD-treated BMDCs to induce the conversion of CD4+CD25- CD4+ T 
cells into CD4+CD25+ Foxp3+ T cells. Compared to vehicle-treated BMDCs, 
TCDD-treated BMDCs decreased the frequency and the number of CD4+CD25+ 
Foxp3+ T cells (Figure 4-1). 
LPS-activated, TCDD-treated BMDCs do not suppress antigen-specific T 
cell activation in vivo: We previously demonstrated that TCDD-treated BMDCs, 
displaying high expression of suppressive mediators fail to suppress antigen- 
specific T cell activation in an OT II adoptive transfer model. Recent studies have  
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Table 4-3: AhR activation by natural ligand FICZ alters gene expressiona 
 
 
 FICZ-induced fold change in AhR 
wildtype BMDCs 
p value 
IDO 1 7.4* 0.003 
IDO 2 14* 0.001 
TGFβ1 0.5 0.11 
TGFβ2 2.2* 0.006 
TGFβ3 9.3* 0.001 
Ltbp3 0.8 0.12 
Aldh1a2 1.2* 0.02 
Thbs 0.7 0.5 
 
 
aGene expression was evaluated from  BMDCs by qRT-PCR. The results are 
expressed as FICZ-induced fold change after normalization with the 
housekeeping gene, β actin. The experiment was conducted with N = 3 per 
treatment group. * p≤ 0.05 indicates significant differences between vehicle-
treated  and FICZ-treated BMDCs. 
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linked AhR activation in DCs with suppression of T cell responses (Hauben et al., 
2008). These studies demonstrated AhR-activated DCs to suppress T cell 
responses only following LPS stimulation. Immature BMDCs did not alter T cell 
responses. Thus, we also evaluated the expression of the suppressive mediators 
in BMDCs following 8 hours LPS maturation. TCDD-treated BMDCs stimulated 
with LPS displayed increased levels of IDO1, IDO2 and TGF-β3 as compared to 
LPS-stimulated, vehicle-treated BMDCs (Table 4-4). We next tested the ability of 
LPS-activated, TCDD-treated BMDCs to suppress antigen-specific T cell 
activation in vivo using a modified OT II adoptive transfer model. LPS-activated, 
vehicle- or TCDD-treated BMDCs were pulsed in vitro with ova-peptide to 
generate ova-loaded DCs capable of activating adoptively transferred, ova-
specific OT II CD4+ T cells in vivo. Peripheral lymph nodes were harvested on 
day 5 following BMDC immunizations. No effects on the number, frequency or 
activation profile of donor DCs were observed in mice receiving LPS-activated, 
TCDD-treated BMDCs as compared to LPS-activated, vehicle-treated BMDCs 
(Figure 4-2). Ova-specific OT II T cells from the popliteal lymph nodes exhibited 
significant clonal expansion when compared to the OT II T cells from non-
draining BLNs, indicating antigen-specific activation. However, no differences in 
the frequency, number or the activation profile of the OT II T cells were detected 
in mice immunized with antigen-laden, LPS-stimulated donor BMDCs treated 
with vehicle or TCDD. 
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Table 4-4 
 
Effects of 8 hours LPS stimulation on TCDD-induced regulatory gene 
expression in BMDCs. 
  
 TCDD-induced fold change following 8 
hrs LPS stimulation 
p value 
IDO 1 15* 0.0004 
IDO 2 14* 0.002 
TGFβ1 1.7 0.05 
TGFβ2 -2.3 0.01 
TGFβ3  5.7* 0.003 
Aldh1a -2.6* 0.01 
Thbs1 1.0 0.5 
 
 
 
aGene expression was evaluated by qRT-PCR in vehicle- and TCDD-treated 
BMDCs stimulated with LPS for 8 hours. The results are expressed as TCDD-
induced fold change when compared to vehicle-treated controls after 
normalization to the housekeeping gene, β actin. The experiment was conducted 
with N = 2 per treatment group. *p ≤ 0.05 was considered significant for all 
analysis conducted between vehicle-treated  and TCDD-treated BMDCs. 
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Figure 4-1 
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Figure 4-1. Effects of TCDD-treated BMDCs on the generation of Foxp3+ 
Tregs from conventional CD4+ T cells.  
Ova-peptide loaded, vehicle or TCDD BMDCs were co-cultured with purified 
CD4+CD25- OT II T cells in 6 well plates at a 1:4 DC to T cell ratio at a final 
concentration of 1 x106 total cells per well. After 4 days in culture, cells were 
harvested and the frequency and number of CD4+CD25+Foxp3+ T cells 
determined. Data represent mean ± SEM of n=3 per treatment group. * p ≤ 0.05 
indicates significant differences between vehicle- and TCDD–treated groups 
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Figure 4-2  
                                                                                            Vehicle                    TCDD 
% CD86 35 ± 3.6 38 ± 10.3 DC activation markers 
% MHC II 62 ± 3.7 55 ± 3.2 
CD62 L MFI 284 ± 18        302 ± 36 T cell activation markers 
CD44 MFI 2150± 119 1884 ± 87.4 
 
 
Figure 4-2. Effects of LPS-matured, TCDD-treated, ova-peptide loaded 
BMDCs on antigen-specific T cell proliferation in vivo: CD4+ T cells from OT 
II Thy1.1 mice were adoptively transferred into CD45.1 host mice, 24 hours 
before immunization with LPS-stimulated, ova-peptide loaded BMDCs, that were 
either vehicle- or TCDD-treated. On day 5 post-immunization, popliteal lymph 
nodes were harvested and the donor DCs and donor T cells analyzed by flow 
cytometry as described in materials and methods. Data represent mean ± SEM 
of 4-5 animals per treatment group. * p ≤ 0.05 indicates significant differences 
between vehicle-  and TCDD–treated groups. 
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DISCUSSION 
We have previously reported that AhR activation by TCDD induces a 
regulatory phenotype in DCs characterized by an increased expression of IDO1, 
IDO2 and TGF-β3 mRNA levels. However, these studies did not address the 
effects of regulatory DCs on T cell differentiation, specifically the generation of 
regulatory T cells.  In this study, we have assessed the role of the AhR and DRE-
mediated events in the induction of regulatory mediators in DCs and evaluated 
the potential of AhR-activated BMDCs to induce adaptive Tregs.  
TCDD-induced toxicity is associated with activation of both DRE and non–
DRE-mediated AhR signaling pathways. We have previously demonstrated that 
TCDD modulates BMDC differentiation via mechanisms that are strictly AhR-
dependent but not exclusively DRE-mediated (unpublished data). Consistent with 
these studies, TCDD-induced expression of regulatory mediators in BMDCs was 
found to be AhR-dependent. The potential involvement of DREs in the 
expression of these mediators was further assessed using BMDCs from 
AhRdbd/dbd and AhRnls/nls mice harboring a mutant AhR that binds ligand but fails 
to translocate to the nucleus or bind to DREs, respectively. TCDD did not 
significantly increases the expression of IDO1 or IDO2 in AhRdbd/dbd or AhRnls/nls 
BMDCs, suggesting that their induction by TCDD required binding of the 
activated AhR to the DREs. Conversely, TCDD increased expression of both 
TGF-β2 and TGF-β3 in AhRdbd/dbd and AhRnls/nls BMDCs. Interestingly, increases 
in TGF-β3 expression by TCDD in both AhRdbd/dbd and AhRnls/nls BMDCs were 
less compared to TCDD-induced increases in AhRdbd/- control BMDCs suggesting 
that TCDD-induced expression of TGF-β2 and TGF-β3 expression in 
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inflammatory BMDCs may be partially regulated by DRE-mediated events. Other 
genes that were slightly but significantly upregulated in AhRnls/nls BMDCs 
following TCDD treatment included Thbs1 and Aldh1a. Aldh1a, an enzyme 
involved in the production of retinoic acid is implicated in the production of Tregs 
(Elias et al., 2008). A slight but significant increase in Aldh1a expression in 
AhRnls/nls BMDCs following TCDD treatment suggests the involvement of 
cytoplasmic, non-DRE mediated signaling events in the induction of regulatory 
mediators following AhR activation.  
Recently studies have identified natural ligands for the AhR such as the 
tryptophan photoproduct, FICZ. Initial studies demonstrated that FICZ, a high 
affinity AhR agonist, can induce Th17 differentiation and inhibit Treg (Quintana et 
al., 2008). In contrast, Kimura et al., reported Treg induction by TGF-β that was 
enhanced when the AhR was activated by either TCDD or FICZ (Kimura et al., 
2008). FICZ has been shown to increase the expression of CD86 on human 
U937 monocyte-derived DCs (Veldhoen et al., 2008; Vogel et al., 2008). So far 
few studies have described the effects of natural AhR ligands on DCs. We have 
previously demonstrated that FICZ can generate phenotypical alterations in 
BMDCs, similar to TCDD in BMDCs, demonstrating a lack of AhR ligand 
specificity in DCs.  These results raised the possibility that similar to TCDD, AhR 
activation by FICZ could also induce the generation of regulatory DCs. FICZ 
increased the expression of IDO1, IDO2, TGF-β2 and TGF-β3 and Aldh1a. 
Although, we have not validated the activity of these suppressive mediators, 
these results suggest that AhR-activation by FICZ could contribute to Treg 
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development. However, further studies are needed to examine the effects of 
FICZ-treated DCs on the polarization of T cells into Th17 or Tregs cells. 
  
Several investigators have linked the generation of immune suppression 
following TCDD exposure to the induction of Tregs (Marshall et al., 2008; 
Quintana et al., 2008; Veldhoen et al., 2008). In a graft versus host model, 
Marshall and colleagues demonstrated the suppressive function of TCDD-CD4+ 
T cells to be independent of Foxp3 expression, suggesting that ligand-activated 
AhR functions as an alternative to Foxp3 in naïve T cells (Marshall et al., 2008). 
Conversely, TCDD-induced suppression of EAE and diabetes in NOD mice has 
been linked to increased Foxp3 expression (Kerkvliet, 2009). Despite these 
studies, the mechanisms underlying the generation of AhR-induced Tregs remain 
poorly understood.  
Recent studies have suggested that DCs can induce Foxp3+ Tregs from 
Foxp3- precursors in the presence of exogenous TGF-β (Sakaguchi et al., 2008). 
TCDD-treated BMDCs showed increased expression of TGF-β3, IDO1 and IDO2, 
raising the possibility that interactions of AhR-activated DCs with Foxp3- cells 
could promote the generation of adaptive/inducible Tregs. Contrary to our 
expectations, Foxp3+ cells were not induced by TCDD-treated BMDCs. 
Additionally, TCDD-treated BMDCs stimulated with LPS failed to suppress 
antigen-specific T cell activation in vivo. These results were surprising, as LPS-
matured, TCDD-treated BMDCs displayed increased mRNA levels of IDO1, IDO2 
and TGF-β3, indicative of a regulatory phenotype. Several possibilities could 
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account for these observed effects. It is possible that TCDD does not increase 
the function or activity of these mediators. In the absence of functionally active 
DC-derived regulatory mediators, TCDD-treated BMDCs would not be expected 
to induce Foxp3+ T cells. Several investigators have identified novel populations 
of adaptive Tregs including CD4+CD25+Tregs, CD4+CD25-Foxp3- Tregs, IL-10-
induced Tregs, TGFβ-induced Tregs and CD8+CD28-Foxp3+ T cells (Weiner, 
2001; Barrat et al., 2002; Zheng et al., 2002; Apostolou and von Boehmer, 2004; 
Chen et al., 2004; Kretschmer et al., 2005; Battaglia et al., 2006; Roncarolo et 
al., 2006; Hansen et al., 2007). The possibility that TCDD-treated BMDCs induce 
the generation of one or more of these distinct Treg populations remains to be 
tested. Studies described herein have exclusively assessed the effects of TCDD-
treated DCs on the induction of adaptive Tregs. It remains to be tested whether 
TCDD-treated DCs affect the maintenance or the expansion of natural Tregs. 
In summary, we have demonstrated that although AhR activation induces 
a regulatory phenotype in DCs, it does not contribute to induction of Treg. Our 
results suggest that the generation of Tregs following AhR activation may not be 
entirely attributable to DCs and that AhR activation of T cells may be essential for 
the induction of regulatory T cells.  
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CHAPTER 5 
CONCLUSIONS 
 
AhR activation by TCDD profoundly suppresses cell-mediated and 
humoral immune responses. However, the specific mechanisms and molecular 
targets underlying these immunotoxic effects remain undefined. Studies have 
shown that expression of the AhR is inducible in lymphocytes and the debate 
whether lymphocytes are direct or indirect targets of AhR activation continues. In 
this context, it has been hypothesized that dendritic cells (DCs), that express 
AhR constitutively, may be directly affected by TCDD and induce suppression of 
T-cell mediated immune responses. To address this hypothesis Vorderstrasse 
and colleagues, initially characterized the effects of AhR activation in DCs. Their 
study demonstrated a decrease in splenic DCs concomitant with modulation of 
maturation markers (Vorderstrasse and Kerkvliet, 2001). Although TCDD 
decreased splenic DC numbers, no effect on the in vivo or in vitro antigen 
processing ability of these DCs was observed. Later studies by Ruby et al., 
documented TCDD to suppress NF-kB/Rel activation (Ruby et al., 2002). Despite 
these studies establishing DCs sensitivity to AhR activation, the consequences of 
AhR activation on the innate and adaptive function of DCs remained undefined. 
To address this deficiency, we investigated the consequences of AhR activation 
on the fate and function of DCs. We postulated that AhR activation generates 
defects in DCs, contributing to aberrant innate and adaptive immune responses, 
culminating in TCDD-induced immune suppression.  
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In our study we first examined the effects of AhR activation in steady-state 
DCs in naïve mice. TCDD altered DC homeostasis by selectively decreasing the 
CD11chighCD8α-33D1+ splenic DCs subset specialized at activating CD4+ T cells 
but did not affect the regulatory CD11chighCD8α+DEC205+ splenic DCs. Thus, 
decreases in the CD4+ T cell activating DCs by TCDD may significantly increase 
susceptibility to infectious agents, especially pathogens that are considered 
blood-borne. Corroborating these in vivo findings, recent data from our laboratory 
has shown TCDD to decrease LPS- and CpG-induced IL-6 and TNF- α 
production by Flt3L-derived, steady-state DCs in vitro (unpublished data). 
Following pathogenic insult, TCDD-induced decreases in proinflammatory 
cytokine production by DCs may lead to defective pathogenic clearance. Thus, 
disruption of DC homeostasis as well as modulation of DC differentiation 
following AhR activation would prevent DCs from effectively activating CD4+ T 
cells, resulting in defective CD4+ T cell responses and immune suppression. 
 
Recently, several reports have linked TCDD-induced immune suppression 
with induction of Tregs (Funatake et al., 2005; Marshall et al., 2008). However, 
little information exists on the mechanisms underlying induction of Tregs and 
subsequent immune suppression following TCDD exposure. Dendritic cells 
contribute to the generation of Tregs via multiple mechanisms. One such 
mechanism is the production of Treg-inducing mediators such as IDO and TGF-
β. Studies from our laboratory have shown an increased production of regulatory 
 
 
 163 
mediators including both IDO and TGF-β3 by steady-state DCs treated with 
TCDD (unpublished data). Therefore, induction of Tregs and subsequent immune 
suppression following TCDD exposure could result not only from a selective 
retention of Treg-inducing CD11chighCD8α+DEC205+ DCs in the periphery, but 
also from an increased production of suppressive mediators by steady-state 
DCs. Taken together, in naive mice, AhR activation disrupts DC homeostasis, 
inducing a loss of DCs that contribute to CD4+ T cell activation. The selective 
loss of this subset, concomitant with the retention of Treg-inducing DCs may 
increase susceptibility to infection and contribute to defective adaptive immune 
responses following TCDD exposure. 
 
 Dendritic cells exist in multiple, functionally distinct stages of 
differentiation both in vitro and in vivo. These include but are not limited to the 
steady-state DCs and inflammatory DCs. As previously described, TCDD altered 
steady-state DC homeostasis and differentiation. Inflammatory DCs, on the other 
hand, constitute a novel DC population that are absent in the steady-state and 
appear only following an inflammatory insult. Because we observed disruption of 
steady-state DC homeostasis, we assessed the direct effects of AhR activation in 
inflammatory DCs and the contribution of AhR-activated DCs in the generation of 
inflammatory responses. TCDD induced a regulatory phenotype in inflammatory 
DCs characterized by an increased expression of the suppressive mediators 
IDO1, IDO2 and TGF-β3. The induction of a regulatory phenotype in 
inflammatory DCs raised the possibility that interactions of these DCs with T cells 
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may generate regulatory T cells or suppress T cell responses directly. 
Surprisingly, despite the induction of regulatory mediators, AhR-activated DCs 
did not suppress T cell activation, raising the possibility that AhR activation in 
both T cells and DCs may be essential for Treg induction or suppression of T cell 
activation. This possibility is consistent with studies from our laboratory 
describing the effects of AhR activation in DCs during the generation of antigen-
specific T cell responses. In our study, host mice treated with TCDD displayed 
increased deletion of donor, antigen-laden DCs contributing to decreased 
expansion of antigen-specific T cells. Though results from these experiments 
demonstrated the requirement for the AhR in DCs to be essential for the 
suppression of antigen-specific T cell responses, they did not exclude the 
possibility that antigen-specific CD4+ T cells may be direct targets of AhR 
activation resulting in suppression of T cell activation.  
Recently, several non-DRE-mediated or non-canonical AhR signaling 
mechanisms underlying toxic manifestations of TCDD have been identified. Of 
these, interactions of activated AhR with NF-kB signaling components were 
shown to induce defects in DCs following TCDD exposure (Ruby et al., 2002; 
Vogel et al., 2008; Vogel and Matsumura, 2008). Consistent with these findings, 
in our study, TCDD-induced modulation of inflammatory BMDCs and TLR 
responsiveness was only partially dependent on DRE-mediated events and led to 
altered NF-kB signaling. In addition to NF-kB signaling, an activated AhR 
interacts with other transcription factors such as retinoblastoma and E2F1. 
Assessing the potential interactions of the AhR with these transcription factors 
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and others may provide further insight into mechanisms by which AhR activation 
modulates DC function. 
Traditionally referred to as an orphan receptor, recent studies have 
identified candidate natural ligands for the AhR ranging from dietary components 
such as flavones to bilirubin. In our study, natural AhR ligands, 6-
formylindolo[3,2-b]carbazole (FICZ) and 2-(1H-Indol-3-ylcarbonyl)-4-
thiazolecarboxylic acid (ITE) altered  DC differentiation suggesting that 
endogenous or natural AhR ligands can also induce immunomodulation. 
Additionally, recent studies have revealed physiological functions of the AhR. In 
one of these studies, the AhR was shown to negatively regulate LPS-induced 
inflammatory responses in macrophages, demonstrating that the physiologic 
function of the receptor extends beyond mediating the toxicities of exogenous 
environmental pollutants (Kimura et al., 2009). Characterizing the effects of 
natural AhR ligands and their specific mechanisms in immune cells may provide 
insights into the physiological functions of the AhR receptor in the immune 
system and help devise strategies by which AhR activation can be therapeutically 
exploited. 
Taken together, our research describes the effects of AhR activation in 
steady-state and inflammatory DCs and identifies mechanisms that may underlie 
TCDD-induced immune suppression. Our results show that AhR activation 
induces defects in DCs that could contribute to the generation of defective CD4+ 
T cell responses and subsequent immune suppression. In addition to DCs and 
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CD4+ T cells, many different types of immune cells express the AhR. Future 
studies examining the consequences of interactions between DCs and immune 
cells such as the Natural Killer cells, B cells and CD8+T cells, in the context of 
AhR activation, may unravel additional mechanisms underlying TCDD-induced 
immune suppression and help understand the normal physiological function of 
the AhR. 
 
. 
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